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Glossary of terms 
(Terms underlined first time used in text) 
A cross sectional survey is a descriptive (epidemiological) study in which the status of a 
group of individuals is assessed at a point in time, with respect to the presence or absence of 
both the exposure(s) and disease(s) of interest. 
Committal prisoners are prisoners who have been admitted to the prison within the preceding 
48 hours, accused or guilty of a new crime, excluding those on temporary release or 
transferred from another prison. The committal population includes individuals entering on 
remand, following sentence, committed as a result of a bench warrant, and non-nationals 
without valid documents. 
Prevalence estimates the proportion of the population that have a disease at a specific point or 
period in time. 
Random sampling is a technique used to select the survey sample from the total population of 
interest by which every member has an equal chance of being selected. 
A confidence interval is the range of values in which the true value of a parameter (e.g. 
proportion) is likely to be found. By convention a 95% confidence interval is usually 
calculated i.e. the range that will include the true value 95% of the time. 
A p-value is a probability value which measures the likelihood that an observed result 
occurred due to chance alone. Probability is measured between the range 0-1. By convention 
a value of p <0.05 is considered statistically significant (for health related studies). 
X2 test is a statistical test to determine if there is a statistically significant association between 
two grouped variables. 
Multiple logistic regression analysis is a statistical technique employed to estimate the level 
of association between one or more variables and a binary outcome of interest while 
controlling for a number of confounding factors (other factors independently associated with 
both the exposure and the outcome). The odds ratio is used to measure the association. 
The odds ratio calculates the ratio of the odds of exposure among the cases (those with the 
disease) to that among the controls (those without the disease). An odds ratio of 1 implies the 
same experience among the cases and the controls. An odds ratio less than 1 implies the 
exposure is protective and an odds ratio greater than 1 implies those exposed have a higher 
risk of contracting the disease. 
Response rate is the proportion of the selected sample who take part in a study. 
IgG is a test which ensures that the specimen is of adequate quality for analysis. 
RIBA is a confirmatory test for hepatitis C. 
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Summary 
The results of a census survey of 1205 Irish prisoners, published in August 1999, showed that 
the prevalence of infection with hepatitis B was 9%, the prevalence of infection with hepatitis 
C was 37%, and the prevalence of infection with HIV was 2%. The current report presents the 
results of a survey of committal prisoners. The reason the committal survey was undertaken 
was to ensure adequate representation of short-term prisoners, and to determine if the 
prevalence of the infections differed in committal prisoners from that found in ‘resident’ 
prisoners. 
Five of the seven Irish committal prisons were included in the survey. A total of 607 prisoners 
took part in the survey, a response rate of 96%. The survey consisted of completing a four 
page questionnaire and collecting a sample of oral fluid for testing for antibodies to hepatitis 
B, hepatitis C and HIV. The fieldwork was carried out between 6th April and 1st May 1999. 
Overall the prevalence of infection with hepatitis B among committal prisoners was 6%, the 
prevalence of infection with hepatitis C was 37% and the prevalence of HIV was 2%. Almost 
one quarter (140/596) of the committal prisoners tested had evidence of at least one of the 
three infections. Prevalence in women prisoners was significantly higher: 22% for hepatitis B, 
56% for hepatitis C, and 10% for HIV. Prevalence was also higher among drug users (18% 
for hepatitis B, 72% for hepatitis C, and 6% for HIV) and in the Dublin prisons. 
Multivariate logistic regression analyses showed that injecting drug use was by far the most 
important predictor of hepatitis B and hepatitis C infection. Female gender was an 
independent risk factor for all three infections. Reporting treatment for sexually transmitted 
infection, and increasing time spent in prison, were also associated with higher rates of 
hepatitis C. Among injecting drug users, sharing needles in prison and high frequencies of 
injecting in the previous month were linked to increased risk of hepatitis C infection. The 
prevalence of HIV was higher in those who had spent more than three of the last 10 years in 
prison. 
Comparison of census and committal surveys 
Respondents in the committal survey were significantly younger than in the census survey. 
For example, 27% of the committal population were less than 20 years old compared to 15% 
of the census population. The sentence profile differed in the two surveys. A higher 
proportion of the committal prisoners were on remand: 53% compared to 13% in the census 
population. Only 17% (88) of committal respondents reported having been in prison for more 
than three of the last 10 years compared to 46% in the census survey. Although the overall 
prevalence for hepatitis B and hepatitis C was lower in the committal population, the 
proportions of injecting drug users infected with hepatitis B, hepatitis C and HIV were similar 
in both surveys. 
The proportion of committal prisoners who reported completing the three dose course of 
hepatitis B vaccination was significantly lower (10%) than in the census survey (29%); this 
was partly explained by the high proportion of first time committals to prison. 
There were fewer drug users among the committals: 31% reported smoking heroin in the last 
year and 29% reported ever injecting drugs compared to 46% and 43% respectively in the 
census survey. The injecting drug using respondents in both surveys were similar with respect 
to age of starting to inject and the time interval between the last time they injected and 
committal to prison. However injecting practices in the two surveys differed. Although a 
higher proportion of injectors in the census survey reported not injecting in the month prior to 
the survey, the proportion sharing injecting equipment, both in and out of prison, was higher 
than in the committal survey. 
The proportion of injectors reporting that they first started injecting in prison was similar in 
both surveys: 17% (30/173) in the committal survey and 21% (104/506) in the census survey. 
The main findings were similar in both the census and committal surveys. There are large 
numbers of injecting drug users in the Dublin prisons, many of whom continue to inject while 
in prison. Most of these drug users are infected with hepatitis C and there are significant 
numbers with hepatitis B and HIV. The hepatitis B vaccination programme is not reaching 
many of those at risk. Over the next decade hepatitis C is likely to be responsible for 
significant morbidity in Irish prisoners. 
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1 Introduction 
1.1 Rationale for the study 
Two studies which examined the sociological and criminological profile of prisoners in 
Mountjoy Male Prison between 1986 and 1996 identified that there was a growing problem 
with injecting drug use and HIV infection.1, 2 However, these studies were based on self 
reporting, were confined to one prison in the Mountjoy Complex, and did not specifically 
include hepatitis B and hepatitis C. There was clearly a need to quantify, using laboratory 
based assessments, the extent of drug related infections in all Irish prisons. 
The results of a census survey estimating the prevalence of hepatitis B, hepatitis C and HIV in 
1,205 prisoners were published in August 1999.3 The second phase of this work: a survey of 
607 committal prisoners is presented here. The terms of reference in the Request for Proposal 
are given in Appendix 1. The reasons for the committal survey were to ensure adequate 
representation of short-term prisoners (long-term prisoners are likely to be over represented in 
a census survey) and to determine if the prevalence of the infections differed in this 
substantial subgroup. There were 11,131 committals to Irish prisons in 1998; if they have a 
different profile this would affect the overall prevalence for hepatitis B, hepatitis C and HIV 
in Irish prisoners. 
Committal prisoners are prisoners who have been admitted to the prison within the preceding 
48 hours, accused or guilty of a new crime, excluding those on temporary release or 
transferred from another prison. The committal population includes individuals entering on 
remand, following sentence, committed as a result of a bench warrant, and non-nationals 
without valid documentation. 
The census survey of Irish prisoners conducted from August to October 1998 revealed that the 
overall prevalence of infection with hepatitis B among this group was 9%, the prevalence of 
infection with hepatitis C was 37% and the prevalence of infection with HIV was 2%.3 
The results of the committal survey are presented in this report and, where appropriate, 
compared with the census survey.3 
1.2 Study objectives 
The objectives of the survey were to: 
• measure the prevalence of three blood-borne viral infections: hepatitis B, hepatitis C 
and HIV, among committal prisoners in high and medium risk Irish prisons. 
• estimate the extent of hepatitis B immunisation in the committal prisoner population. 
• determine the extent of self-reported risk behaviours, in particular injecting drug use, 
in committal prisoners and the association of these behaviours with prevalence. 
• compare self-reported prevalence of hepatitis B, hepatitis C and HIV with actual 
prevalence in committal prisoners. 
• compare reported risk behaviours and prevalence in the committal survey with the 
findings in the census survey. 
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2 Methods 
2.1 Sampling 
The annual committal population in Ireland is approximately 11,000, committed to seven 
prisons: Cork, Castlerea, Limerick, Mountjoy Male and Female, Portlaoise and St. Patrick’s 
Institution. For sampling purposes, prisons were categorised as high risk (3 prisons), medium 
risk (3 prisons) and low risk (1 prison) based on the predicted prevalence of infection. All 
except two prisons, Castlerea and Portlaoise, were included in the survey. These prisons were 
excluded as the numbers omitted are very small and it would have been difficult to maintain 
confidentiality. (The number of committals to Castlerea was 136 in 1998; only a very small 
number of high security prisoners (approximately 50) are committed annually to Portlaoise.) 
The five prisons included were Mountjoy Male and Female, and St. Patrick’s Institution (high 
risk) and Cork and Limerick (medium risk). Based on the predicted prevalence of hepatitis c 
infection, it was estimated that a sample size of 534 was required. Given the usual committal 
rate, it was estimated that it would take three to four weeks to collect a sample of this size. 
The survey was carried out from 6th April to 1st May 1999. The fieldwork involved visiting 
each prison daily during this period and interviewing all those committed within the previous 
48 hours. The list of committals was obtained from the committal register maintained in each 
prison. Prisoners who were considered unstable were placed in a secure environment for 24 
hours and interviewed the following morning. None of the prisoners committed during the 
survey period were considered a security risk for the interviewers. Six individuals who were 
unable to provide informed consent were excluded from the survey. Due to space constraints 
or the nature of the prisoners’ offence, 85 committals were released or transferred from the 
committals area before they could be interviewed. 
2.2 Fieldwork 
As in the census survey, preparatory work was carried out in each prison through 
correspondence and meetings between the research team and the prison governor and key 
staff. The approach taken in carrying out the survey varied slightly in different prisons 
according to the prison conditions, wishes of the prison authorities, and the time prisoners 
were usually transferred from the courts. Staff and prisoners were briefed in advance of the 
survey through individual information leaflets. 
The survey was carried out by a team of researchers who met the prisoners individually or in 
pairs. The survey team was briefed in advance and consisted of health professionals or 
experienced researchers (Appendix 2). A health professional was available at all times to 
answer questions of a medical nature. The prisoners were given an introductory talk lasting 
five minutes, explaining the purpose and process of the survey. They were advised that all 
data collected would be anonymous and confidential and that no information that could 
identify an individual would be released to the prison authorities or to the Department of 
Justice, Equality and Law Reform. Prisoners were informed that they would not be able to get 
their individual test results from the survey, but were advised that testing was available 
through the prison medical service. They were invited to ask questions or make comments. 
With the agreement of the prisoners, the survey then proceeded. 
Prisoners who did not wish to provide an oral fluid sample were asked to complete a 
questionnaire. The survey was voluntary. All eligible prisoners were encouraged to participate 
but no inducements were offered and no negative sanctions were imposed on non-
respondents. 
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2.3 Data collection instruments 
There were two parts to the survey: collection of an oral fluid specimen and completion of a 
questionnaire (Appendices 3a and 3b). In order to complete the process as quickly as possible, 
the questionnaire was generally filled in while the oral fluid specimen was being collected. 
The questionnaire consisted of closed, multiple choice questions and was similar to that used 
in the Irish prison census survey with minor adaptations. The questions relating to 
demography, history of injecting drug use, self-reported HIV and hepatitis testing and results, 
and hepatitis B vaccination history were the same as those used in the census survey. The 
questions covering details of prison sentences were adapted to suit the committal population. 
Additional questions on sexual practices were included and prisoners were asked about 
tattooing inside and outside prison. The respondents were encouraged to complete the 
questionnaire themselves; this took an average of five minutes. A researcher assisted those 
who had difficulties. The survey was anonymous – no name, address or other identifier was 
recorded on either the questionnaire or the oral fluid specimen. Once completed, the 
questionnaire and oral fluid specimen were placed in an envelope and all envelopes were then 
placed in a collection bag. A number was later assigned to each questionnaire and specimen, 
linking the two. At the end of each day of fieldwork the questionnaires were checked for 
internal consistency. 
The survey procedures, including the use of the questionnaire and the oral fluid testing, were 
piloted on committal prisoners in Mountjoy prison and minor alterations were made 
subsequently. 
On the survey day, anonymous demographic information was gathered on the entire 
committal prison population in each prison to calculate response rate and establish 
representativeness of respondents. 
2.4 Collection of oral fluid specimens 
Oral fluid specimens were collected with a proprietary device called EpiScreen™ (Epitope 
Inc., Oregon, USA). It consists of a cotton fibre pad treated with a hypersonic salt solution on 
a plastic stick. Capillaries lining the gum and cheek mucosae leak significant amounts of 
plasma proteins, including immunoglobulins, into the mouth. EpiScreen™ pad is designed to 
collect oral fluid specimens rich in this capillary transudate (‘oral mucosal transudate’). The 
pad is placed between the lower gum and cheek and held in place for at least two minutes. 
After collection, the pad is placed in a tube, provided as part of the collection kit, containing a 
non-toxic preservative solution that inhibits bacterial growth and degradation of 
immunoglobulins. Once specimens are collected they can be stored for up to 21 days at 
temperatures between 4°C and 37°C. For this study, specimens were kept refrigerated until 
transported in several large batches by overnight courier to the Central Public Health 
Laboratory in the United Kingdom. Laboratory processing of the specimens commenced on 
the next working day and the specimens were tested blind to demographic and risk factor 
characteristics. The laboratory techniques used by the Central Public Health Laboratory are 
described in Appendix 4. 
2.5 Explanation of laboratory tests used 
The laboratory test used on the oral fluid specimens was different for each of the three viruses 
examined. Knowledge of what each test implies is necessary to interpret the test results, and a 
brief description of each test is given here. 
The hepatitis B antibody test used in this survey measures antibodies to the hepatitis B core 
antigen. This is a measure of ever having been infected ‘naturally’ with the hepatitis B virus. 
Best available evidence is that the long-term carrier rate, and hence infectivity of someone 
who has ever been infected with hepatitis B is 10%4. The anti hepatitis core test in this survey 
has a sensitivity of 82% (18% false negative) and specificity greater than 99% (less than 1% 
false positive). 
For hepatitis C, the Central Public Health Laboratory tests for antibodies to the hepatitis C 
virus. The presence of antibodies to hepatitis C virus indicates previous or current infection; 
in 80% to 85% of cases the infection persists.5, 6 The sensitivity of the antibody test used in 
4 
this survey is estimated to be 80%. This means that the false negative rate is 20%: one in 
every five who test negative are actually positive. The specificity was 100% which implies 
that all test results which are positive are truly positive. 
The test for antibodies to the HIV virus used in this survey is a measure of ever having been 
infected with HIV. Best knowledge is that people who have ever been infected with HIV 
remain infectious for the duration of their lifetime. Both sensitivity and specificity for the 
antibody test to HIV used in this survey were greater than 99% (manufacturer’s data). 
2.6 Statistical methods 
Data entry was carried out using an automated procedure7 and was subsequently checked 
manually. Statistical analysis was carried out using JMP IN8, and Stata. 
Pearson X2 test, and Fisher’s exact test were used to compare proportions in independent 
groups of categorical data. The X2 test for trend was used to identify linear trends in 
categorical data. Multiple logistic regression models were developed to determine which 
variables best predicted positive antibody results. Exact 95% confidence intervals were 
calculated for proportions of binomial variables and for regression adjusted odds ratios. 
 
 
5 
3 Results 
The results of this study are presented in nine sections. 
3.1 General information including response rate, age and gender profile and prison history 
of the respondents. 
3.2 Prevalence of hepatitis B, hepatitis C and HIV. 
3.3 Hepatitis B vaccination. 
3.4 Prevalence and characteristics of drug use. 
3.5 Sexual practices. 
3.6 Tattooing. 
3.7 Analysis of factors contributing to increased risk of hepatitis B, hepatitis C and HIV. 
3.8 Comparison with the census survey.3 
3.9 Estimated the total numbers of cases of hepatitis B, hepatitis C and HIV in the Irish 
prison population. 
The frequency distributions of the responses to all questions are given in appendix 5. 
Table totals vary throughout as not all respondents answered all questions. 
To preserve confidentiality, most analyses are given by prison group rather than by individual 
prison. 
Relevant comparisons with the census survey3 are provided in Section 3.8. The frequency 
distributions of the responses to the census survey questionnaire are given in appendix 6. 
3.1 General information 
3.1.1 Response rates 
The governors of the five selected prisons agreed to the survey; 607 out of 633 prisoners 
agreed to participate in the survey, an overall response rate of 96%; 596 prisoners contributed 
an analysable oral fluid sample. The response rate for each prison is shown in Table 1. Just 
over 5% (31) of the respondents said they had participated in the census survey, and two 
respondents were recommitted during the survey period (not shown separately in tables). 
Table 1 – Committal survey response rate by prison 
Prison Committal 
population 
during the 
survey 
period 
Released or 
transferred 
immediately 
Sample 
available 
Exclusions Refusals Number 
responded 
Response 
rate 
(%) 
High risk 
Mountjoy Male 
Mountjoy Female 
St Patrick’s 
 
343 
47 
176 
 
45 
9 
21 
 
298 
38 
155 
 
2 
 
1 
 
7 
 
3 
 
289 
38 
151 
 
97 
100 
97 
Medium risk 
Cork 
Limerick M&F 
 
95 
57 
 
6 
4 
 
89 
53 
 
1 
2 
 
4 
6 
 
84 
45 
 
94 
85 
Total 718 85 633 6* 20 607# 96 
* 6 individuals were excluded from the survey as it was not possible to obtain informed consent (language or psychological 
difficulties). 
# 10 respondents did not provide an oral fluid sample and one sample was inadequate for analysis. Two individuals did not 
complete the questionnaire but provided samples. 
6 
3.1.2 Age and gender of respondents 
The age profile of the respondents was similar to that of the overall population of the five 
participating prisons at the time of the survey (Figure 1) (X2 = 0.9, df 5, p = 0.97). As 
anticipated, the prison population was very young. Over half (56.0%) the respondents were 
less than 25 years of age and 74 (12.3%) were less than 18 years of age (Appendix 5). 
Just over 7% (43/607) were women. The age distribution was similar in men and women (X2 
= 0.9, df 4, p = 0.92). Five (6.8%) of the 74 committals under 18 years were female. 
Figure 1 – Age profile of prison population and committal survey respondents 
 
3.1.3 Prison history 
Only 43.5% of the respondents had been sentenced prior to committal while the remainder 
were in on remand (52.7%), or on a warrant (3.7%) or for extradition (0.2%) (Figure 2). More 
than one third of the respondents (38%, 201) said they had never been in prison before. 
Within the committal population, the majority of prisoners had not been sentenced. Over one 
fifth (21.1%, 127) of the respondents had been committed to prison more than 5 times. 
Almost half (36) of the 74 respondents aged less than 18 had never been in prison before but 
one had spent more than three of the past 10 years in prison. Sixty three (85%) of these young 
prisoners were detained in St. Patrick’s Institution. 
Figure 2 – Committal survey respondents current sentence 
3.2 Prevalence of hepatitis B, hepatitis C and HIV 
Prevalence was determined using antibody assays of oral fluid (Section 3.2.1). These rates 
were compared with self-reported infection status (Section 3.2.2). Although most of those 
with infections reported injecting drug use or sexual risk behaviours, some respondents had 
evidence of infection without apparent risk factors. This finding is discussed in Section 3.2.3. 
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3.2.1 Prevalence of antibodies in oral fluid 
Table 2a presents the prevalence of the three blood-borne viral infections. Hepatitis C was by 
far the most common with 22% of respondents (130/596) testing positive. Hepatitis B was 
less common with 6.2% testing positive (37/596). HIV was relatively uncommon: only 12 
respondents (2.0%) tested positive. 
As expected, infection rates were significantly higher in the high risk prisons. For example, 
27.3% of respondents were positive for hepatitis C in the high risk prisons compared to 0.8% 
in the medium risk prisons (Table 2a). The three Dublin prisons, Mountjoy Male and Female, 
and St. Patrick’s Institution, had been defined for sampling purposes as high risk prisons as 
they were known to have illicit drug problems (see Methods). The proportion of respondents 
in these three prisons who reported ever injecting drugs was 36.2%, significantly higher than 
the 1.6% in the medium risk i.e. non-Dublin prisons (see Table 7, Section 3.4.1). The high 
infection rates in the high risk prisons are consistent with the high infection risks in injecting 
drug users (see below). 
Table 2a – Prevalence of hepatitis B, hepatitis C and HIV in committal prisoners by prison category 
 All 
Total: 596 
No. (%) 
95% CI 
High risk 
Total: 473 
No. (%) 
95% CI 
Medium risk 
Total: 123 
No. (%) 
95% CI 
Test of association 
Hepatitis B positive 37 (6.2) 
4.4-8.5 
35 (7.4) 
5.2-10.1 
2 (1.6) 
0.2-5.7 
Testing positive for hepatitis B was 
significantly more likely in 
prisoners committed to a high risk 
prison 
Pearson X2 = 5.6, df = 1, p < 0.02 
Hepatitis C positive 130 (21.8) 
18.6-25.4 
129 (27.3) 
23.3-31.5 
1 (0.8) 
0.02-4.4 
Testing positive for hepatitis C was 
significantly more likely in 
prisoners committed to a high risk 
prison 
Pearson X2 = 40.1, df=1, p < .0001 
HIV positive 12 (2.0) 
1.0-3.5 
10 (2.1) 
1.0-3.8 
2 (1.6) 
0.2-5.7 
Pearson X2 = 0.1, df = 1, p = 0.73. 
NS 
NS = not significant 
The three infections were far more common in those who reported ever injecting drugs or 
smoking heroin (in the last year) than in non-users (Table 2b and 2c). Hepatitis C was more 
common in those under 30 than in those aged 30 or over (Table 2d). The highest infection rate 
for hepatitis C was found in those aged 20-24 years (not shown in table). Infection rates were 
significantly higher amongst the women (Table 2e): hepatitis C was almost three times higher 
in women than men, hepatitis B was four times higher, while HIV was seven times more 
likely in women. These differences are likely to be attributable to the fact that the proportion 
of female committals reporting injecting drug use was considerably higher, at 60.5%, than the 
equivalent figure for men (26.6%) (see Table 8). Respondents never previously in prison had 
a much lower prevalence than those previously imprisoned. Prevalence rates for all three 
infections increased significantly with increasing time spent in prison (Table 2f). 
Seven of the 74 respondents under 18 years of age were hepatitis C positive; four were 
positive for hepatitis B and none HIV positive. 
Table 2b – Prevalence of hepatitis B, hepatitis C and HIV in committal prisoners by injecting drug use (IDU) 
 IDU 
Total: 173 
No. (%) 
95% CI 
Non IDU 
Total: 420 
No. (%) 
95% CI 
Test of association 
Hepatitis B positive 31 (17.9) 
12.5-24.5 
5 (1.2) 
0.4-2.8 
Testing positive for hepatitis B was significantly 
associated with reported injecting drug use 
Pearson X2 = 60.1, df = 1, p < .0001 
Hepatitis C positive 124 (71.7) 
64.3-78.3 
6 (1.4) 
0.5-3.1 
Testing positive for hepatitis C was significantly 
associated with reported injecting drug use 
Pearson X2 = 353.2, df = 1, p < .0001 
HIV positive 10 (5.8) 
2.8-10.4 
2 (0.5) 
0.1-1.7 
Testing positive for HIV was significantly 
associated with reported injecting drug use 
Pearson X2 = 17.4, df = 1, p  < .0001 
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Table 2c – Prevalence of hepatitis B, hepatitis C and HIV in committal prisoners by heroin smoking in the last year 
 Smoked heroin 
 
Total: 184 
No. (%) 
95% CI 
Did not smoke 
heroin 
Total: 409 
No. (%) 
95% CI 
Test of association 
Hepatitis B positive 27 (14.7) 
9.9-20.6 
10 (2.4) 
1.2-4.5 
Testing positive for hepatitis B was 
significantly associated with reported heroin 
smoking 
Pearson X2 = 32.4, df = 1, p < .0001 
Hepatitis C positive 103 (56.0) 
48.5-63.3 
26 (6.4) 
4.2-9.2 
Testing positive for hepatitis C was 
significantly associated with reported heroin 
smoking 
Pearson X2 = 183.6, df = 1, p < .0001 
HIV positive 8 (4.3) 
1.9-8.4 
4 (1) 
0.3-2.5 
Testing positive for HIV was significantly 
associated with reported heroin smoking 
Pearson X2 = 7.3, df = 1, p = < 0. 01 
Table 2d – Prevalence of hepatitis B, hepatitis C and HIV in committal prisoners by age 
 < 30 yr 
Total: 427 
No. (%) 
95% CI 
> 30 yr 
Total: 166 
No. (%) 
95% CI 
Test of association 
Hepatitis B positive 24 (5.6) 
3.6-8.2 
12 (7.2) 
3.8-12.3 
Pearson X2= 0.5 df = 1, p < 0.46 
NS 
Hepatitis C positive 109 (25.5) 
21.5-29.9 
19 (11.4) 
7.0-17.3 
Testing positive for hepatitis C was significantly 
more likely in respondents under 30 years of age. 
Pearson X2 = 14.0, df = 1, p < .0001 
HIV positive 6 (1.4) 
0.5-3.0 
6 (3.6) 
1.3-7.7 
Pearson X2= 2.9 df = 1, p < 0.09 
NS 
NS = not significant 
Table 2e – Prevalence of hepatitis B, hepatitis C and HIV in committal prisoners by gender 
 Women 
Total: 41 
No. (%) 
95% CI 
Men 
Total: 555 
No. (%) 
95% CI 
Test of association 
Hepatitis B positive 9 (22.0) 
10.6-37.6 
28 (5.0) 
3.4-7.2 
Testing positive for hepatitis B was 
significantly more likely in women. 
Pearson X2 = 18.7, df = 1, p < .0001 
Hepatitis C positive 23 (56.1) 
39.8-71.5 
107 (19.3) 
16.1-22.8 
Testing positive for hepatitis C was 
significantly more likely in women. 
Pearson X2 = 30.3, df = 1, p < .0001 
HIV positive 4 (9.8) 
2.7-23.1 
8 (1.4) 
0.6-2.8 
Testing positive for HIV was 
significantly more likely in women. 
Pearson X2 = 13.4, df = 1, p = 0.0003 
Table 2f – Prevalence of hepatitis B, hepatitis C and HIV in committal prisoners by time spent in the last 10 year 
  
None 
Total: 197 
No. (%) 
95% CI 
Time spent in prison 
1 day–3 years 
Total: 235 
No. (%) 
95% CI 
 
< 3 years 
Total: 87 
No. (%) 
95% CI 
Test of association 
Hepatitis B positive 4 (2.0) 
0.6-5.1 
20 (8.5) 
5.3-12.8 
10 (11.5) 
5.7-20.1 
Prevalence of hepatitis B increased 
significantly with increased length of 
time spent in prison. 
X2 for trend = 10.9, p < 0.001 
Hepatitis C positive 5 (2.5) 
0.8-5.8 
62 (26.4) 
20.9-32.5 
53 (60.9) 
49.9-71.2 
Prevalence of hepatitis C increased 
significantly with increased length of 
time spent in prison. 
X2 for trend = 118.3, p < 0.0001 
HIV positive 1 (0.5) 
0.01-2.8 
4 (1.7) 
0.5-4.3 
7 (8.0) 
3.3-15.9 
Prevalence of HIV increased 
significantly with increased length of 
time spent in prison. 
X2 for trend = 11.8, p < 0.0006 
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Figure 3 shows the inter-relationship between the three infections; 23.5% of prisoners had 
evidence of infection with at least one virus. Most of those who had antibodies to hepatitis B 
or HIV also had antibodies to one or more of the other two viruses (78.4% and 83.3% 
respectively) whereas only 26.2% (34/130) of those infected with hepatitis C had an 
additional infection. 
Figure 3 – Number (%) of committal prisoners oral fluid test positive for hepatitis B, hepatitis C and 
HIV and the overlap between the infections, N = 596 (100%) 
 
3.2.2 Comparison of prevalence from self-reporting and from oral fluid assays 
The self-reported prevalence for each infection (calculated as a proportion of the total survey 
population) was lower than the prevalence derived from the oral fluid assays (Table 3). Using 
self reports to estimate prevalence for all committal prisoners would therefore have under-
estimated the scale of the infection problem. The majority of respondents said they had not 
been tested previously. Others did not know whether they had been tested for the viruses, and 
of those who said they had been previously tested, a considerable number said they did not 
know the result. 
Table 3 – Comparison of proportions positive for oral fluid test with self-reported status in committal 
prisoners, as a percentage of the total survey population and as a percentage of those tested 
Self-reported status   
 
 
 
Antibody 
status 
By oral fluid 
test 
 
 
 
No. (%) 
% of total survey 
 population 
No. (%) 
% of those tested 
 
No. (%) 
Hepatitis B Positive 
Negative 
Do not know 
Total 
 37 (6.2) 
 559 (93.8) 
  
 596 (100) 
 21 (3.4) 
 
 
 607 (100) 
21 (17.3) 
84 (69.4) 
16 (13.2) 
121 (100) 
Hepatitis C Positive 
Negative 
Do not know 
Total 
 130 (21.8) 
 446 (78.2) 
 
 596 (100) 
 89 (14.7) 
 
 
 607 (100) 
89 (69.0) 
25 (19.4) 
15 (11.6) 
129 (100) 
HIV Positive 
Negative 
Do not know 
Total 
 12 (2.0) 
 584 (98.0) 
 
 596 (100) 
 11 (1.8) 
 
 
 607 (100) 
11 (6.5) 
126 (74.1) 
33 (19.4) 
170 (100) 
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The respondents who reported previous tests for any of these infections differed from the 
wider group in that they were more likely o be drug users. For example, those who reported 
having had a test for: 
• hepatitis C were 16 times more likely to report injecting drug use (65.7% of injectors 
said they had had a test compared to only 4.0% of non injectors); 
• hepatitis B were 10 times more likely to report injecting drug use; 
• HIV were five times more likely to report injecting drug use (see Appendix 5). 
Tables 4a-4c show the number of respondents who reported a previous negative test result but 
tested positive to the oral fluid assay and vice versa. (Note: The numbers in these tables relate 
only to respondents who knew their test results.) Almost one quarter (6/25) who claimed to 
have had a negative test result for hepatitis C had a positive oral fluid test result. The 
proportion of those testing positive but reporting negative was lower for hepatitis B (12/84) 
and for HIV (2/126). It was surprising to note that 60% (6/10) of those who reported being 
HIV positive, tested negative on the oral fluid assay, while almost half who self reported 
being hepatitis B positive tested negative. Only three (3.4%) of those who reported that they 
were hepatitis C positive were negative on the oral fluid test. Possible reasons for these 
discrepancies include: mistakes in filling out the questionnaire, misunderstanding the 
question, deliberate misrepresentation, change in antibody status since the previous test, and 
test error (including low test sensitivity for hepatitis B and C, and discrepancies between 
different laboratories). 
 
Oral fluid 
Test result 
Reported hepatitis B result 
Positive Negative 
 
Positive 
Negative 
 11 12 • 
 9* 72 
 23 
 81 
  20 84  104 
Table 4a – Self-reported hepatitis B status and the oral 
fluid test results in committal prisoners 
• Respondent reported negative hepatitis B status but tested positive 
∗ Respondent reported negative hepatitis B status but tested positive 
Oral fluid 
Test result 
Reported hepatitis C result 
Positive Negative 
 
Positive 
Negative 
 85 6 • 
 3* 19 
 91 
 22 
  88 25  113 
Table 4b – Self-reported hepatitis C status and the oral 
fluid test results in committal prisoners 
• Respondent reported negative hepatitis C status but tested positive 
∗ Respondent reported negative hepatitis C status but tested positive 
Oral fluid 
Test result 
Reported HIV result 
Positive Negative 
 
Positive 
Negative 
 4 2 • 
 6* 124 
 6 
 130 
  10 126  136 
Table 4c – Self-reported hepatitis HIV status and the oral 
fluid test results in committal prisoners 
• Respondent reported negative HIV status but tested positive 
∗ Respondent reported negative HIV status but tested positive 
3.2.3 Infections among respondents with no risk factors 
Of the 607 respondents, 370 reported having none of the main risk factors (i.e. said they had 
never injected drugs, never had anal sex with a man either inside or outside prison, and never 
been treated for a sexually transmitted infection). Among this subgroup, three respondents 
tested hepatitis B positive, five hepatitis C positive and two HIV positive. All were men. 
Thirty-two of these 370 reported smoking heroin in the last year; two of these had hepatitis C. 
When respondents who smoked heroin, had tattoos, or had been paid for sex were excluded, 
there still remained one case of hepatitis B, one of hepatitis C and two cases of HIV who had 
no reported risk factors. None of these four respondents had more than one infection and none 
of them reported having been aware that they had one of the infections. 
Inaccurate self-reporting of risk behaviours might explain these infections in respondents with 
no apparent risk factors. (Inaccurate reporting is always a potential problem in surveys, 
particularly with sensitive topics such as illicit drug use and sexual practices). Alternatively 
they may have had a partner whose sexual history was unknown to them. Or they may have 
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been infected through needle stick injuries, infected blood products or other unidentified 
routes of infection such as sharing razors and/or toothbrushes. 
3.3 Uptake of hepatitis B vaccine 
Self reported vaccine uptake rate is shown in Table 5. Vaccine uptake overall was 
disappointingly low: 
• only 9.8% of respondents reported completing three doses of hepatitis B 
• 11.7% completed one or two doses 
• 78.5% reported not receiving hepatitis B vaccine. 
Coverage was higher in those who had previously spent time in prison (Table 5). Vaccine 
uptake rates were equally low in those who were still susceptible to hepatitis B infection i.e. 
respondents whose antibody status was hepatitis B negative (Table 5). Only two of the 74 
respondents under 18 had completed three doses of hepatitis B vaccine; a further two had 
received one or two doses. 
Nevertheless, 79.1% (91) of the partially or fully vaccinated respondents had been immunised 
in prison. 
Table 5 – Reported hepatitis B vaccination coverage in committals prisoners, respondents previously in 
prison, and hepatitis B negative respondents 
 Completed 
3 doses 
No. (%) 
Completed 
1 or 2 doses 
No. (%) 
Did not receive 
Vaccine 
No. (%) 
Total 
All respondents 55 (9.8) 66 (11.7) 442 (78.5) 563 
Respondents previously spent 
time in prison 
50 (13.2) 62 (16.4) 266 (70.4) 378 
Hepatitis B negative 
respondents 
49 (9.4) 59 (11.4) 410 (79.1) 518 
Table 6a shows the proportions vaccinated by length of time spent in prison over the last ten 
years. It is Department of Justice, Equality and Law Reform policy that all prisoners 
sentenced for eight months (equivalent to serving six months) or more should be offered 
hepatitis B vaccination. Therefore it is not surprising that commencement rates were highest 
in those who had spent more than three of the last 10 years in prison. 
Overall however coverage is low and it is clear that the vaccination programme is targeted to 
long term prisoners but no necessarily to those most at risk (see Tables 6a-6c). 
Table 6a – Reported hepatitis B vaccination coverage in committal prisoners by time spent in prison in 
the last 10 years 
Hepatitis B vaccine 
status 
Time in prison in the past 10 years 
Never 1 day-3 years 
No./Total (%) No./Total (%) 
>3 years 
No./Total (%) 
Test of association 
1 or more doses 7/180 (3.9) 52/228 (22.8) 52/85 (61.2) X2 for trend = 262.9, p < 0.0001 
Respondents who had spent time 
in prison were significantly more 
likely to have started a course of 
hepatitis B vaccine. 
3 doses completed 
(of those who had at 
least 1 dose) 
3/7 (42.8) 18/52 (34.6) 28/52 (53.8) X2 for trend = 2.6, p = 0.11 
NS 
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Table 6b – Reported hepatitis B vaccination coverage in committal prisoners by injecting drug use 
Hepatitis B vaccine status Injecting drug use 
Yes No 
No./Total (%) No./Total (%) 
Test of association 
1 or more doses 79/172 (45.9) 42/390 (10.8) Respondents who were IDUs were significantly 
more likely to have commenced a course of 
vaccine. 
Pearson X2 = 87.3, df = 1, p < 0.0001 
3 doses completed 
(of those who had at least 1 
dose) 
41/79 (51.8) 14/42 (33.3%) Pearson X2 = 31.1, df = 1, p = 0.05 
NS 
Table 6c – Reported hepatitis B vaccination coverage in committal prisoners by hepatitis B status 
Hepatitis B vaccine status Hepatitis status (oral fluid) 
Negative Positive 
No./Total (%) No./Total (%) 
Test of association 
1 or more doses 108/518 (20.8) 13/36 (36.1) Respondents who were oral fluid positive for 
hepatitis B were significantly likely to have 
commenced hepatitis B vaccine 
Pearson X2 = 4.6, df = 1, p = 0. 03 
3 doses completed 
(of those who had at least 1 
dose) 
49/108 (45.4) 6/13 (46.1) Pearson X2 = 0.1, df = 1, p = 0.89 
NS 
3.4 Drug use 
3.4.1 Reported drug use 
Table 7 shows that 186 respondents said they had smoked heroin in the last year and 175 
stated they had (ever) injected drugs. The proportion reporting drug use was much higher in 
the high risk prisons. Overall, 214 of the 604 respondents said hey had used heroin (Figure 4). 
Most, but not all, of those who said they had smoked heroin in the last year had also injected 
drugs and vice versa. 
Table 7 – Proportion of committal prisoners who smoked heroin or ever injected drugs by prison category 
 All 
No./Total (%) 
High 
No./Total (%) 
Medium 
No./Total (%) 
Test of association 
Smoked heroin in the 
last 12 months 
186/604 (30.8) 173/477 (36.3) 13/127 (10.2) Smoking heroin in the last year was 
significantly more common in high 
risk prisons 
Pearson X2 = 31.9, df = 1, p <0.0001 
Ever injected drugs 175/604 (29.0) 173/478 (36.2) 2/126 (1.6) Injecting drug use was significantly 
more common in high risk prisons 
Pearson X2 = 58, df = 1, p= <0.0001 
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Twelve of the 74 respondents under 18 years of age reported smoking heroin in the last year 
and the same number reported ever injecting drugs. 
Women prisoners were more likely to smoke heroin and/or inject drugs. Sixty five percent of 
women respondents reported smoking heroin in the last year compared to 28.2% of male 
respondents; 60.2% of male respondents; 60.5% of women respondents reported ever 
injecting drugs compared to 26.6% of men (Table 8). 
Table 8 – Proportion of committal prisoners who smoked heroin or ever injected drugs by gender 
Gender  
Women 
No./Total (%) 
Men 
No./Total (%) 
Test of association 
Smoked heroin in the 
last year 
28/43 (65.1) 158/561 (28.2) Women were significantly more likely than 
men to report smoking heroin. 
Pearson X2 = 25.6, df = 1, p < 0.0001 
Ever injected drugs 26/43 (60.5) 149/561 (26.6) Women were significantly more likely than 
men to report drug use. 
Pearson X2 = 22.3, df = 1, p < 0.0001 
Almost half the injectors (48.6%, 85) said they had commenced injecting before their 18th 
birthday (Figure 5); 68% (118) had first injected more than three years ago. Sixty six percent 
of injectors said they had injected drugs in the week prior to committal (42.2% in the previous 
24 hours) (Appendix 5). This suggests that most were current drug users. Eight of the 12 
injectors under 18 years of age reported injecting in the previous month. Of the 169 
respondents with a history of injecting drug use, 35 (20.7%) reported injecting 1 to 19 times 
in the previous month while 87 (51.5%) said that they had injected more than 20 times. 
3.4.2 Reported drug using behaviour in prison 
Thirty prisoners (4.9% of the 607 respondents), or 17.3% of injectors (30/173), said they first 
started injecting drugs while in prison. 
A higher number of injectors said they shared needles and syringes inside prison than outside: 
• 64 (40.3%) said they shared needles while in prison whereas 53 (30.8%) said they 
shared in the month before committal 
• 69 (43.4%) said they shared syringes in prison while 57 (33.1%) reported sharing 
outside. 
(Note: no information was asked about the number of times injecting equipment was shared.) 
Seven of the 12 injectors under the age of 18 reported sharing injecting equipment in the 
month before coming into prison, and only one reported sharing injecting equipment in 
prison. 
Those who shared injecting equipment were significantly more likely to be infected with 
hepatitis C than those who did not share (Table 9a). Almost 82% (75) of injectors who said 
they had shared injecting equipment in the month before coming into prison were infected 
with hepatitis  C  compared to  59.5%  (47)  of those who had not shared outside in the month 
Table 9a – Prevalence of hepatitis C committal prisoners in relation to sharing injecting equipment in 
prison or outside 
Shared Outside*  
Yes 
No./Total (%) 
No 
No./Total (%) 
Test of association 
Hepatitis C positive 75/92 (81.5) 47/79 (59.5) Respondents who tested positive for 
hepatitis C were significantly more likely to 
have shared injecting equipment in the 
month prior to committal 
Pearson X2 = 10.1, df = 1, p = 0.001 
 Shared Outside* 
Hepatitis C positive 63/69 (91.3) 53/87 (60.9) Respondents who tested positive for 
hepatitis C were significantly more likely to 
have shared injecting equipment in prison 
Pearson X2 = 18.6, df = 1, p < 0.0001 
*Shared injecting equipment in the month prior to this committal 
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before committal. The excess risk of sharing injecting equipment within the prison 
environment was even greater than sharing outside: 91.3% of those who said they had ever 
shared inside prison were infected with hepatitis C compared to 60.9% of those who had not 
shared in prison The prevalence of hepatitis C increased significantly with an increased 
frequency of injecting in the previous month (Table 9b). 
Table 9b – Prevalence of hepatitis C results in committal prisoners by number of times injected in the last month 
 0 
No./Total (%) 
1-19 
No./Total (%) 
20+ 
No./Total (%) Test of association 
Prevalence of 
hepatitis C 
24/47 (51.1) 24/35 (68.6) 72/85 (84.7) Prevalence of hepatitis C increased 
with an increased frequency of 
injecting 
X2 for trend = 17.5, df = 1, p < 0.0001 
3.4.3 Methadone treatment prior to committal 
Just over a third of the injecting drug users (60/173) said they were on a methadone 
programme prior to committal. This included five of the 12 injectors aged less than 18 years. 
A further three young respondents were on a methadone programme for heroin smokers at the 
time of committal. 
A high proportion of those who said they were on methadone at committal (24/60, 40%) said 
they had injected on the day before entering the prison. A further 17 (28%) said they injected 
in the month before entering this committal. Only 12 (20%) respondents said they had not 
injected in the month prior to committal. Among those registered on a methadone programme: 
• 12/55 had not injected in the last month 
• 24/58 said they had injected more than 20 times in the previous month 
• 20/59 reported that they had shared equipment during previous imprisonment 
• 47/60 tested positive for hepatitis C 
3.5 Sexual practices 
The sexual risk factors reported by respondents are shown in Table 10 separately for injecting 
drug users and non-users. It was our impression that these questions were the least likely to 
have been answered truthfully. 
Most respondents reported heterosexual activity in the year prior to committal. Only nine men  
Table 10 – Reported sexual behaviour and risk factors in committal prisoners by reported IDU and non IDU 
 All 
No./Total (%) 
IDU 
No./Total (%) 
IDU 
No./Total (%) 
Heterosexual intercourse in the 12 
months prior to committal 
539/596 (90.4)) 159/171 (93.0) 380/424 (89.6) 
Number of heterosexual 1-2 
partners in the last 3-9 
year 10+ 
340/536 (63.4) 
149/536 (27.8) 
47/536 (8.8) 
104/157 (66.2) 
43/157 (27.4) 
10/157 (6.4) 
236/379 (62.2) 
106/379 (28.0) 
37/379 (9.8) 
Use condoms during heterosexual 
intercourse 
253/531 (47.6) 64/155 (41.3) 189/376 (50.3) 
Men ever have anal sex with men 9/560 (1.6) 2/148 (1.4) 7/411 (1.7) 
Use condoms during male homosexual 
intercourse 
4/8 (50.0) 1/2 (50.0) 3/6 (50.0) 
Men ever have anal sex with men in 
prison 
3/354 (0.9) 1/131 (0.8) 2/222 (0.9) 
Ever paid for any type of sex 26/559 (4.6) 8/148 (5.4) 18/410 (4.4) 
Ever been paid for any type of sex 15/601 (2.5) 12/171 (7.0) 3/429 (0.7) 
Ever treated for STI* 44/600 (7.3) 27/171 (15.8) 17/428 (4.0) 
* Sexually transmitted infection 
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reported that they had ever had anal sex with a man (1.6% of the 560 men who responded to 
the question), and (0.9% of the 354 who answered the question) reported having had anal sex 
with a man while in prison. These two groups were not necessarily the same men. For 
example two men reported anal sex in prison having previously denied ever having sex with 
another man. 
Other practices of note are listed below: 
• Over half of the survey respondents reported never using condoms during 
heterosexual intercourse. 
• Over one third reported having three or more heterosexual partners in the previous 12 
months; this group was significantly more likely to use condoms (64%) than those 
who reported having one or two partners (36%) (Pearson X2 = 46.6, df 1, p < 
0.0001). 
• Almost 5% of respondents reported having been paid for any type of sex. 
• Only 2.5% of respondents reported having been paid for any type of sex. However 
for all injecting drug users this figure rose to 7% and 21.7% for female injecting drug 
users. 
• 7.3% of respondents reported that they had ever been treated for sexually transmitted 
infections. (A history of sexually transmitted infections in an indicator of “unsafe 
sex”). 
The tables in Appendix 7 show the frequency of the various sexual practices among those 
who tested positive for one or more of the three infections. Relevant features were: 
• Respondents who tested positive for each of the three infections were significantly 
more likely to report ever having been paid for sex. 
• Those who tested positive for hepatitis B and C were significantly more likely to 
report ever having been treated for sexually transmitted infections. 
3.6 Tattooing 
Three hundred and fifty eight respondents reported having a tattoo, almost half of all 
committals. Eighty-nine (25%) were tattooed in prison. One hundred and thirty-three tattoos 
were carried out by an artist, 112 by a friend, and 109 were self-administered. 
Tattooing was significantly associated with injecting drug use (Pearson X2 = 42.7, df 1, p = 
0.0001), smoking heroin (Pearson X2 = 29.4, df 1, p = 0.0001) and increased time spent in 
prison (X2 for trend = 75.5, df 1, p < 0.0001). 
Testing positive for hepatitis C was more common in those with a tattoo than in those without 
a tattoo (29.6% versus 10.3%, Table 11). Among the 87 who had a tattoo done in prison, 
41.4% were hepatitis C positive compared to 26.2% (69/293) among those who had their 
tattoo done outside prison (Table 11). The prevalence of hepatitis C was higher in those who 
had done their own tattoo or had it done by a friend (35.5%) than in those who had it done by 
a tattoo artist (21.4%) (Table 11). 
Table 11 – Tattooing as a risk factor for hepatitis C in committal prisoners 
 Tattoo 
Yes No 
No./Total (%) No./Total (%) 
Test of association 
Hepatitis C positive 105/352 (29.8) 24/241 (10.0) Hepatitis C positive respondents were more 
likely to have a tattoo 
Pearson X2 = 33.1, df = 1, p < 0.0001 
 Tattoo done in prison 
Yes No 
No./Total (%) No./Total (%) 
 
Hepatitis C positive 36/87 (41.4) 69/263 (26.2) Hepatitis C positive respondents were more 
likely to have had their tattoo(s) done in prison 
Pearson X2 = 7.1, df = 1, p = 0.007 
 Tattoo done by: 
Self/friend Artist 
No./Total (%) No./Total (%) 
 
Hepatitis C positive 77/217 (35.5) 28/131 (21.4) Hepatitis C positive respondents were more 
likely to have a self administered or friend 
administered tattoo(s) 
Pearson X2 = 7.7, df = 1, p = 0.005 
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3.7 Risk factors for infection 
Analysis of individual risk factors showed that by far the most important predictor of both 
hepatitis B and hepatitis C was a history of injecting drug use. The link between injecting 
drug use and hepatitis C was particularly strong. 
In order to clarify the links between the risk factors, the factors were combined in multivariate 
analyses (logistic regression), the main findings of which are described below. The 
relationships presented below are those that remained statistically significant after taking 
account of the inter-linking of risk behaviours. (The associations are expressed as odds ratios 
(OR) adjusted for confounding). 
• Respondents with evidence of hepatitis B infection were more likely to be injecting 
drug users and women. Those who reported ever injecting drugs were 15 times more 
likely to be hepatitis B positive than those who did not report injecting (adjusted OR 
15.9, CI 6.5-47.6). (Table 12a) 
• Those positive for hepatitis C were very likely to be injecting drug users (adjusted 
OR 89.1, CI 37.4-255.3); women respondents reporting treatment for sexually 
transmitted infections and respondents who had spent increasing time in prison 
during the last 10 years were more likely to be hepatitis C positive (Table 12b). 
Tattooing was not a significant dependent risk factor. 
Table 12a – Logistic regression model to identify independent associations with hepatitis B infection in the 
committal survey population 
 Total 
sample 
596 
No. 
Hepatitis B 
negative 
559 
No. 
Hepatitis B 
positive 
37 
No. 
Prevalence of 
hepatitis B 
 
% 
Odds 
ratio 
95% CI p-value 
Ever injected 
drugs 
No 
Yes 
Missing 
 
 
420 
173 
3 
 
 
415 
142 
 
 
5 
31 
 
 
1.2 
17.9 
 
 
1 
15.9 
 
 
 
6.5-47.6 
 
 
 
<0.0001 
Gender 
Male 
Female 
Missing 
 
555 
41 
0 
 
527 
32 
 
28 
9 
 
5.1 
21.9 
 
1 
2.7 
 
 
1.1-6.5 
 
 
0.0283 
Whole model X2 = 59 R2 = .22 p <0.0001 
Table 12b – Logistic regression model to identify independent associations with hepatitis C infection in the 
committal survey population 
 Total 
sample 
596 
No. 
Hepatitis C 
negative 
466 
No. 
Hepatitis C 
positive 
130 
No. 
Prevalence of 
hepatitis C 
 
% 
Odds 
ratio 
95% CI p-value 
Ever injected 
drugs 
No 
Yes 
Missing 
 
 
420 
173 
3 
 
 
414 
49 
 
 
6 
124 
 
 
1.4 
71.7 
 
 
1 
89.1 
 
 
 
37.4-255.3 
 
 
 
<0.0001 
Gender 
Male 
Female 
Missing 
 
555 
41 
0 
 
448 
18 
 
107 
23 
 
19.3 
56.1 
 
1 
7.3 
 
 
1.9-35.8 
 
 
0.009 
Total amount of 
time spent in 
prison over the 
last 10 years 
<3 months 
3-11 months 
12-36 months 
>3 years 
Missing 
 
 
 
 
261 
64 
107 
87 
77 
 
 
 
 
248 
48 
69 
34 
 
 
 
 
13* 
16 
38 
53 
 
 
 
 
50 
25.0 
35.5 
60.9 
 
 
 
 
1 
4.9 
5.2 
14.2 
 
 
 
 
 
1.5-17.4 
2.0-14.6 
5.1-43.6 
 
 
 
 
 
0.01 
0.001 
<0.0001 
Ever treated for 
STI 
No 
Yes 
Missing 
 
 
546 
44 
6 
 
 
445 
18 
 
 
101 
26 
 
 
18.5 
59.1 
 
 
1 
7.4 
 
 
 
1.9-33.7 
 
 
 
0.007 
Whole model X2 = 353, R2 = .64 p <0.0001 
*Sexually transmitted infection 
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• Women, and respondents who had spent more than three years in prison had an 
increased risk of HIV infection (Table 12c). The total number testing positive for 
HIV was very small (12/596) and the numbers with the two risk factors were even 
smaller (women: 4, and over three years spent in prison: 7). Therefore inferences 
from this model are limited. 
Table 12c – Logistic regression model to identify independent associations with HIV infection in the 
committal survey population 
 Total 
sample 
596 
No. 
HIV 
negative 
584 
No. 
HIV 
positive 
12 
No. 
Prevalence 
of HIV 
 
% 
Odds 
ratio 
95% CI* p-value 
Gender 
Male 
Female 
Missing 
 
555 
41 
0 
 
547 
37 
 
8 
4 
 
1.4 
9.7 
 
1 
9.6 
 
 
2.3-37.4 
 
 
0.001 
Total amount of 
time spent in 
prison over the 
last 10 years 
<3 months 
3-11 months 
12-36 months 
>3 years 
Missing 
 
 
 
 
261 
64 
107 
87 
77 
 
 
 
 
260 
62 
105 
80 
 
 
 
 
1 
2 
2 
7 
 
 
 
 
0.4 
3.1 
1.9 
8.0 
 
 
 
 
1 
8.4 
4.9 
27.1 
 
 
 
 
 
0.8-185.2 
0.5-107.9 
4.5-521.2 
 
 
 
 
 
0.09 
0.2 
0.003 
Whole model X2 = 23.2, R2 = .20 p <0.0001 
Injecting drug use was clearly the biggest contributor to infection with hepatitis B and 
hepatitis C. Consequently the data have been analysed to identify behaviours that contributed 
to the ‘riskiness’ of injecting. The relationships below are those that remained significant after 
taking account of the inter-linking of risk behaviours (The associations are expressed as odds 
ratios (OR) adjusted for confounding). The detailed models are presented in the tables in 
Appendix 8. 
• Injecting drug users aged 30 or over were almost 5 times more likely than injectors 
under 30 (adjusted OR 4.8, CI 14.1) to have evidence of hepatitis B infection. 
Injectors with a history of more than 10 sex partners in previous 12 months had a 
higher hepatitis B risk than those who had reported having 1-2 partners (adjusted OR 
5.3, CI 1.2-22.3), (see Appendix 8A) 
• Those who reported frequent injecting in the month prior to the survey and injectors 
who had shared needles in prison (adjusted OR 5.9, CI 2.2-18.8) were at increased 
risk of hepatitis C infection. (see Appendix 8B) 
• Injectors drug users age 30 or over were over six times more likely than injectors 
under 30 to have evidence of HIV infection (adjusted OR 7.3, CI 1.8-31.8); 
respondents who had shared needles in the month prior to imprisonment were seven 
times more likely to have evidence of HIV infection (adjusted OR 7.1, CI 1.8-36.7) 
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3.8 Comparison of the committal and census surveys 
3.8.1 Age and gender of respondents 
Respondents in the committal survey were significantly younger than in the census survey X2 
= 63.5, df 6 p-value < 0.0001) (Figure 5). For example, 27.4% (166/607) of the committal 
population were less than 20 years old compared to 15.4% (177/1147) of the census 
population. A higher proportion of the respondents in the committal survey were women: 
7.1% (43/607) compared with 4.7% (57/1205) in the census survey (X2 = 4.3, df 1, p = 
0.0383). 
Figure 5 – Age profile of committal and census survey respondents 
 
3.8.2 Prison history 
The current sentence profile differed from that of the census population in that a higher 
proportion of the committal prisoners were on remand (52.7% v 13.1%) and a further 3.7% 
were committed for a short period on warrant, mainly for non payment of fines or breach of 
the peace. 
The proportion of committals who reported having been in prison for more than three of the 
last 10 years (16.6%) was significantly lower than in the census survey (46.3%). (Figure 6) 
Figure 6 – Time spent in prison in the last 10 years by committal and census survey 
 
X2 = 327.9, df 3, p <0.0001 
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3.8.3 Prevalence of hepatitis B, hepatitis C and HIV 
In general hepatitis infection rates were lower in the committal population (Figure 7), 
although in both surveys the proportions of injecting drug users infected with hepatitis B, 
hepatitis C and HIV were similar (Figure 8) 
Figure 7 – Prevalence of the three infections in committal and census surveys 
 
Figure 8 – Prevalence of the three infections in those reporting IDU in committal and census surveys 
 
Infection rates for hepatitis B, hepatitis C and HIV in women were higher in the committal 
survey than in the census survey, (Figure 9). 
Figure 9 – Prevalence of the three infections in women in committal and census surveys 
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The proportion of the total survey population infected with one or more viruses was lower in 
the committal survey (23.5%) than in the census survey (38.5%). The proportion with more 
than one infection was also slightly lower in the committal survey (8.5%) versus 5.7%). 
In both surveys the levels of discrepancy between self-reported test results and laboratory test 
results were similar. 
3.8.4 Hepatitis B vaccination 
The reported overall hepatitis B vaccine coverage was significantly lower in the committal 
survey: 
• 9.8% of respondents reported completing three doses of hepatitis B compared to 28.9% 
in the census survey. 
• 11.7% completed one or two doses compared to 19.0% in the census survey. 
When first time prisoners were excluded, the vaccine commencement rate was higher in the 
committal survey (29.6% compared to 19.0%), although the completion rate remained lower 
among the committal population (13.2% versus 28.9%). The high proportion of short-term 
prisoners in this population may explain this. 
3.8.5 Drug use 
The proportion reporting drug use was significantly lower in the committal survey than in the 
census survey (smoked heroin: 30.8% versus 45.9%, X2 = 37.9, df 1, p < 0.0001; ever 
injected drugs: 29% versus 43.2%, X2 = 34.6, df 1, p < 0.0001). 
Respondents in both surveys reported starting injecting at similar ages (Figure 10), although a 
higher proportion (82%) of the injecting drug users in the census survey reported 
commencing injecting more than three years ago (X2 = 15.5, df 4, p = 0.0038). This finding 
could be explained by the fact that the committal survey population has a higher proportion of 
young respondents. The proportions relating to the last time the respondents injected before 
committal to prison were also similar in the two surveys (Figure 11). 
Figure 10 – Age stated injecting drugs in the committal and census survey respondents 
 
Figure 11 – Last time drug users injected before committal to prison by committal and census survey 
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Similar proportions of injecting drug users in both surveys reported starting injecting in 
prison: 17.3% (30/173) in the committal survey and 20.6% (104/506) in the census survey, 
(X2 = 0.8, df 1, p = 0.3594). 
Injecting practices in the committal survey were significantly different from those reported in 
the census survey by respondents who had spent more than three months in prison. A higher 
proportion of the census population reported not injecting in the month prior to the survey 
(X2 = 72.6, df 2, p < 0.0001). (Figure 12) This suggests that some injecting drug users 
stopped injecting when in prison. However, compared to the committal population, 
respondents in the census survey reported higher rates of sharing injecting equipment both in 
the month prior to imprisonment (X2 = 7.0, df 2, p = 0.0297), and in prison (X2 = 55.9, df 2, p 
< 0.0001) (Figures 13a and b). 
Figure 12 – Frequency of injecting in the month prior to the survey by committal and census (in prison 
more than 3 months) injecting drug users 
 
Figure 13a – Frequency of sharing injecting equipment in the month before imprisonment by 
committal and census survey 
 
Figure 13b – Frequency of sharing injecting equipment in prison by committal and census survey 
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3.8.6 Sexual practices 
The reported use of condoms was significantly higher in the committal survey (47.6%) than 
in the census survey (33.8%). (X2 = 28.2, df 1, p = 0.0001) 
The proportion of respondents reporting treatment for a sexually transmitted infection was 
significantly higher in the census population (12.6% versus 7.3%) (X2 = 11.5, df 1, p = 
0.001). In both surveys, reporting treatment for sexually transmitted infections was more 
common in injecting drug users than in non-drug users: 15.8% in the committal survey and 
17.3% in the census survey. In the census survey, a history of treatment for sexually 
transmitted infections was more strongly associated with testing positive for hepatitis B and 
HIV than in the committal survey. 
In the census survey men who reported anal sex with men were more likely to test positive for 
hepatitis B and HIV; this association was not found in the committal survey. This could be 
due to the small numbers of men reporting anal sex in the committal survey. 
3.8.7 Risk factors for infection 
Injecting drug use was a risk factor for hepatitis B in both surveys. Age over 29 years and 
treatment for sexually transmitted infections were additional risk factors in the census survey. 
Infecting drug use and time spent in prison were significant risk factors for hepatitis C in both 
surveys, but age less than 30 years and smoking heroin were additional predictors in the 
census survey. 
The risk factors for hepatitis B and hepatitis C in injecting drug users were similar in both 
surveys. 
The predictors for testing positive for HIV in the committal survey (female gender, and time 
spent in prison) differed from those in the census survey (injecting drug use, ever treated for 
sexually transmitted infection and anal sex between men). The risk factors for HIV among 
drug users also differed in the two surveys. This lack of consistency is likely to be due to 
small numbers in both surveys. 
3.9 Estimated numbers of cases of hepatitis B, hepatitis C and HIV in the Irish 
prison populations 
3.9.1 Estimated numbers of cases among those residing in prison September to 
November 1998 
In the census survey, just under 54% of high and medium risk prisoners were tested for 
hepatitis B, hepatitis C and HIV; 44.8 % of all prisoners were tested. The proportion of 
positive cases for each infection among the samples tested was applied to the prison 
population in the medium and high risk category at the time of the survey to estimate the total 
number of cases in these populations. 
The total expected numbers of cases in the prison population at the time of the survey were 
calculated using the estimated numbers of cases in high and medium risk prisons, plus the 
expected number of cases in low risk prisons using relevant scenarios outlined in Appendix 9 
(i.e. population prevalence and prevalence among non drug users in medium risk prisons). 
The estimates of the numbers infected with hepatitis B and HIV using two different sets of 
assumptions were similar (Appendix 9). The estimated total number of people with hepatitis 
B infection residing in Irish prisons at the time of the census survey was between 204 and 
215, and the estimated number of people with HIV infection was between 47 and 56. Using 
the single assumption available, the estimated number infected with hepatitis C was between 
869 and 883. 
3.9.2 Estimated numbers of cases among those committed to prison in 1998 
Individuals may be committed to prison more than once in the year1, 9 but the approximate 
number of re-committals for a given year is not available. The Department of Justice, 
Equality and law Reform were unable to provide the percentage of re-committals in 1998 and 
for reasons of confidentiality could not provide us with access to files. It is anticipated that 
the system will be computerised in 2000 and will then be able to provide estimates of re-
committals annually. Until these estimates are available, it is not possible to provide realistic 
estimates of the numbers of infected persons entering Irish prisons. 
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4 Discussion 
When compared with the resident population,3 the committal population differed in that there 
was a higher proportion of younger prisoners, women, and respondents who have spent less 
than three months in the last 10 years in prison. The prevalence of injecting drug use was 
significantly lower, as was the overall prevalence of hepatitis B and hepatitis C. 
The prevalence of these infections in injecting drug users was similar in both surveys and 
reflects the prevalence found in injecting drug users in the community (Dr. J. Barry, personal 
communication). 
In the committal survey women were more likely than men to be hepatitis B and hepatitis C 
positive and to report injecting drug use. Even after taking account of the inter-linking risk 
factors and behaviours, women were three times more likely to test positive for hepatitis B 
(OR 2.7, CI 1.1-6.5), seven times more likely to test positive for hepatitis C (OR 7.3, CI 1.9-
35.8) and almost 10 times more likely to test positive for HIV (OR 9.6, 2.3-37.4). 
The numbers with HIV were very small which makes it difficult to draw conclusions about 
the risk behaviours associated with this infection. There were two undiagnosed cases of HIV 
among the respondents tested. The value of offering routine testing to high risk categories 
such as prisoners may be considered in the future as research has shown that current treatment 
regimes for HIV positive individuals, when commenced early, extend survival and prevent 
damage to the immune system.10, 11 In both survey, a sizeable number of respondents were 
found who reported they were HIV positive when in fact they tested negative. On committal 
to prison, it may be advisable to offer any individual who thinks s/he is HIV positive a 
confidential test to confirm their HIV status. One should not underestimate the psychological 
effects of thinking one is HIV positive. 
Between 30 and 60% of those with chronic liver disease as a result of hepatitis C infection 
will develop chronic active hepatitis and, of these, 5-20% will develop cirrhosis of the liver.4 
This will contribute to the future burden of disease within deprived communities in Ireland. In 
the USA, recent research into drug therapy for hepatitis C has yielded encouraging findings; 
during initial treatment using combination therapy, 31-38% had cleared the virus from their 
system when tested 24 weeks later,12 while 49% of relapsed cases had a similar outcome.13 It 
would be advisable for the prison health authorities to continue to review research and to 
consider proactive treatment as more effective protocols are developed. 
The reported age distribution of starting to inject was similar in both the committal and 
census surveys, although injecting and sharing practices were different. Similar injecting 
habits and sharing practices among injecting drug users in the community and in prison have 
been reported elsewhere;14 injecting drug users in the community tended to inject more 
frequently and shared less frequently than those imprisoned. Individuals who were 
imprisoned injected less frequently but had more harmful sharing practices. 
In the committal survey, tattooing was associated with hepatitis C. When the links between 
injecting drug use and length of time in prison were accounted for, the association between 
tattooing and hepatitis C was no longer significant. 
Also of note was that one sixth of injecting drug users reported treatment for sexually 
transmitted infections, and, in the committal survey, were more likely to sell six for income. 
The prevalence of sexually transmitted infections in the Irish prison population has not been 
assessed to date although the link with HIV and hepatitis B is well established. The presence 
of a sexually transmitted disease will accelerate the progression of HIV. Sexually transmitted 
infections can be easily treated in sentenced prison population. 
24 
In both surveys hepatitis B vaccination coverage was low, although due to the high proportion 
of first time prisoners, the coverage was even lower among the committal prisoners. The 
vaccine was targeted towards long term prisoners but not towards those who are hepatitis B 
negative. Vaccine completion rates were lower in the injecting drug users. This may be 
because the importance of competing the vaccine was not clear to the injecting drug users or 
because they do not think the vaccine is important or useful. In discussions with the prisoners 
many of the prisoners had misinformation about hepatitis B and hepatitis C that may 
influence their evaluation of the effectiveness of the vaccine. The purpose of, number of 
doses, and target group for the vaccine need to be clarified with all prisoners. Hepatitis B 
vaccine is considered very effective; prisoners and also injecting drug users are high risk 
populations for this disease. The vaccine is now available to medical card holders within the 
high risk population and therefore it would be advisable for all prisoners to have the vaccine 
on committal, regardless of their length of sentence, as follow up doses can be given by their 
GPs or in drug treatment centres. 
Prisoners suffer from a range of sensitive and serious medical conditions. Confidentiality, 
counselling and education are required to deal with these conditions. The provision of these 
skills in the interests of prisoner health and well-being would require a multidisciplinary 
team, independent of the prison security function. 
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5 Recommendations 
The findings in this survey support the recommendations made in the census survey in 
particular, the need for: 
• Active infectious disease control and surveillance 
• Provision of harm reduction measures for injecting drug users 
• Health services provided by an independent multidisciplinary team. 
Further recommendations are outlined below. 
• As treatments for hepatitis C improve, the introduction of a proactive treatment regime 
for sentenced prisoners through referral to a hepatologist should be considered. 
• A proactive approach to identifying HIV positive prisoners and commencing 
appropriate therapy. 
• Confidential HIV testing for all prisoners who think they may have the infection should 
be provided. 
• Prisoners, in particular drug users, should be offered screening for sexually transmitted 
infections on committal, and treatment if necessary. 
• Prisoners need to be informed of the potential dangers of tattooing using non-sterile 
equipment. 
• There is a strong case for the provision of more health information on hepatitis and its 
prevention to counteract misinformation that exists about hepatitis B and hepatitis C, 
and hepatitis B vaccination. 
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Appendix 1 
Request for Proposal 
Department of Justice, Equality and Law Reform 
PRISONS DIVISION RESEARCH PROGRAMME 
REQUEST FOR PROPOSAL (RFP 
 
2. LEVEL OF HIV AND HEPATITIS INFECTION AMONG PRISONER POPULATION 
1 Background 
The Department of Justice, Equality and Law Reform is embarking on a research programme in 
relation to various matters within its area of responsibility. Several of these matters fall under the 
remit of the Prisons Division. Prisons Division has responsibility for the provision and 
maintenance of a secure, efficient and progressive system of containment and rehabilitation for 
offenders committed to custody. The Division aims to treat offenders while in custody with care, 
justice, dignity and respect with particular emphasis on health, education, training and offender 
welfare. 
2 Project 
In this context, the Prisons Division is seeking to establish levels of HIV and Hepatitis infection 
among the prisoner population. The project involves 
♦ 
♦ 
♦ 
♦ 
♦ 
♦ 
♦ 
♦ 
the design of an appropriate anonymous questionnaire; 
the organisation of the completion of this questionnaire across a wide representative 
sample of the prisoner population; 
the organisation of a complimentary programme of saliva testing; 
the compilation of the results of the questionnaire; and 
the study of those results and the production of a finished report on the findings. 
Accordingly the Department hereby invites proposals for the provision of the above service. 
Proposals should include 
a detailed outline of the methodology 
timescale; and 
total cost of the research exercise 
INVITATION TO TENDER 
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Appendix 2 
Survey Team 
Dr Shane Allwright Senior Lecturer in Epidemiology∗ 
Dr Joseph Barry Public Health Doctor 
Dr Fiona Bradley General Practitioner 
Ms Una Cronin Research Nurse, MSc 
Ms Carrie Garavan Research Nurse, MPH 
Ms Jean Long Research Nurse, MSc∗ 
Ms Geraldine McCullough Research Nurse, MSc∗ 
Ms Ailbhe Mealy Executive Officer∗ 
Ms Sheilagh Reaper-Reynolds Research Officer, MSc∗ 
Dr Leila Thornton Public Health Doctor 
∗affiliated with the Department of Community Health and General Practice 
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Appendix 3a 
Questionnaire for male respondents 
  
 ANONYMOUS SURVEY OF HIV & HEPATITIS SURVEY IN IRISH PRISONS 
  
Please answer by filling in the circles like this ............................................... o 
1 Have you taken part in this survey BEFORE? 
Yes................................  o 
No .................................  o 
If yes, how many times on committal_______ 
as an inmate______ 
2 How OLD are you? (in years) _________ 
3 Are you 
On remand ..................................................  o 
Sentenced ...................................................  o 
Other______________________________  o 
4 How many TIMES have you been in prison? 
Never ........................  o 
1-5 times........................  o 
More than 5 times..........  o 
5 How much of the last 10 YEARS have you spent in prison?________ 
6 Do you have a tattoo? 
Yes ........................  o 
No ........................  o 
If yes, did you have it done in prison...........  o 
outside ........................  o 
Who did it?……. Self..................................  o 
Friend/Relative ........................  o 
Tattoo Artist ........................  o 
7 In the LAST YEAR have you smoked (chased) heroin? 
Yes................................  o 
No .................................  o 
8 Have you EVER INJECTED drugs? 
Yes................................  o 
No .................................  o 
If YES, please turn to next page 
If NO, please go to Question 16* on Page 3  
9 How OLD were you when you first injected drugs? ________ 
 (in years) 
1 
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 09 How OLD were you when you first injected drugs?  ________ 
  (in years) 
10 Were you in prison the FIRST time you ever injected? 
Yes ........................  o 
No ........................  o 
11 How many TIMES have you injected in the last month? ________ 
12 When was the LAST time you injected BEFORE coming into 
prison? 
On the day you came into prison  ...................  o 
In the week before  .........................................  o 
In the month before  .......................................  o 
In the year before  ..........................................  o 
More than 1 year before  ................................  o 
13 In the MONTH BEFORE coming into prison, had you SHARED any of 
these works with someone else: 
- needles (spikes)? Yes ........................  o 
 No ........................  o 
- syringes (barrels)? Yes ........................  o 
 No ........................  o 
- others? Yes ........................  o 
- (filters, spoons etc.) No ........................  o 
14 Are you on a methadone programme? 
Yes ........................  o 
No ........................  o 
15 If you were IN PRISON BEFORE did you ever SHARE any of these 
works with someone else during your sentence: 
- needles (spikes)? Yes ........................  o 
 No ........................  o 
- syringes (barrels)? Yes ........................  o 
 No ........................  o 
- others? Yes ........................  o 
(filters, spoons etc.) No ........................  o 
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 HALF WAY THERE!!! 
 
16* In the 12 MONTHS BEFORE coming into prison did you have 
vaginal sex with a women? 
Yes ........................  o 
No ........................  o 
If yes, with how many women 
1-2 ........................  o 
3-9 ........................  o 
more than 9...................  o 
Did you use condoms? 
Always/Sometimes .........  o 
Never  ........................  o 
17 Did you EVER have anal sex with another man? 
Yes ........................  o 
No ........................  o 
If yes, did not use condoms? 
Always/Sometimes .........  o 
Never  ........................  o 
18 Did you ever have anal sex IN PRISON with another man? 
Yes ........................  o 
No ........................  o 
Does not apply .........  o 
19 Have you ever you ever PAID money, goods or drugs for any type 
of sex? 
Yes ..............................  o 
No ..............................  o 
20 Have you ever BEEN PAID money, goods or drugs for any type of sex? 
Yes ..............................  o 
No ..............................  o 
21 Have you ever been treated for an STD? (sexually transmitted disease) 
Yes ..............................  o 
No ..............................  o 
Please turn to last page    
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 22 Have you ever had a blood test of HIV? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
If yes, what was the result? 
Positive (infected) .............  o 
Negative (not infected) .......  o 
Don’t know ........................  o 
23 Have you ever had a blood test for hepatitis B? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
If yes, what was the result? 
Positive (infected) .............  o 
Negative (not infected) .......  o 
Don’t know ........................  o 
24 Have you been vaccinated against hepatitis B? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
If yes, were you vaccinated in prison? 
Yes ...............................  o 
No ...............................  o 
If vaccinated, have you had the complete 
course of 3 injections? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
25 Have you ever had a blood test for hepatitis C? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
If yes, what was the result? 
Positive (infected) .............  o 
Negative (not infected) .......  o 
Don’t know ........................  o 
THANKS FOR TAKING PART  
PLEASE PUT THE SALIVA AND QUESTIONNAIRE 
IN THE ENVELOPE  
4 
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Appendix 3b 
Questionnaire for male respondents 
  
 ANONYMOUS SURVEY OF HIV & HEPATITIS SURVEY IN IRISH PRISONS 
  
Please answer by filling in the circles like this ............................................... o 
1 Have you taken part in this survey BEFORE? 
Yes................................  o 
No .................................  o 
If yes, how many times on committal_______ 
as an inmate______ 
2 How OLD are you? (in years) _________ 
3 Are you 
On remand ..................................................  o 
Sentenced ...................................................  o 
Other______________________________  o 
4 How many TIMES have you been in prison? 
Never ........................  o 
1-5 times........................  o 
More than 5 times..........  o 
5 How much of the last 10 YEARS have you spent in prison?________ 
6 Do you have a tattoo? 
Yes ........................  o 
No ........................  o 
If yes, did you have it done in prison .......................  o 
outside ........................  o 
Who did it?…………… Self..................................  o 
Friend/Relative ........................  o 
Tattoo Artist ........................  o 
7 In the LAST YEAR have you smoked (chased) heroin? 
Yes................................  o 
No .................................  o 
8 Have you EVER INJECTED drugs? 
Yes................................  o 
No .................................  o 
If YES, please turn to next page 
If NO, please go to Question 16* on Page 3  
9 How OLD were you when you first injected drugs? ________ 
 (in years) 
1 
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 10 Were you in prison the FIRST time you ever injected? 
Yes ........................  o 
No ........................  o 
11 How many TIMES have you injected in the last month? ________ 
12 When was the LAST time you injected BEFORE coming into 
prison? 
On the day you came into prison  ...................  o 
In the week before  .........................................  o 
In the month before  .......................................  o 
In the year before  ..........................................  o 
More than 1 year before  ................................  o 
13 In the MONTH BEFORE coming into prison, had you SHARED any of 
these works with someone else: 
- needles (spikes)? Yes ........................  o 
 No ........................  o 
- syringes (barrels)? Yes ........................  o 
 No ........................  o 
- others? Yes ........................  o 
- (filters, spoons etc.) No ........................  o 
14 Are you on a methadone programme? 
Yes ........................  o 
No ........................  o 
15 If you were IN PRISON BEFORE did you ever SHARE any of these 
works with someone else during your sentence: 
- needles (spikes)? Yes ........................  o 
 No ........................  o 
- syringes (barrels)? Yes ........................  o 
 No ........................  o 
- others? Yes ........................  o 
(filters, spoons etc.) No ........................  o 
2 
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 HALF WAY THERE!!! 
 
16* In the 12 MONTHS BEFORE coming into prison did you have 
vaginal sex with a man? 
Yes ........................  o 
No ........................  o 
If yes, with how many men 
1-2 ........................  o 
3-9 ........................  o 
More than 9...................  o 
Did you use condoms? 
Always/Sometimes .........  o 
Never  ........................  o 
17 Have you ever BEEN PAID money, goods or drugs for any type of sex? 
Yes ........................  o 
No ........................  o 
18 Have you ever been treated for an STD? (sexually transmitted disease) 
Yes ........................  o 
No ........................  o 
Please turn to last page    
3 
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 20 Have you ever had a blood test of HIV? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
If yes, what was the result? 
Positive (infected) .............  o 
Negative (not infected) .......  o 
Don’t know ........................  o 
21 Have you ever had a blood test for hepatitis B? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
If yes, what was the result? 
Positive (infected) .............  o 
Negative (not infected) .......  o 
Don’t know ........................  o 
22 Have you been vaccinated against hepatitis B? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
If yes, were you vaccinated in prison? 
Yes ...............................  o 
No ...............................  o 
If vaccinated, have you had the complete 
course of 3 injections? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
23 Have you ever had a blood test for hepatitis C? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
If yes, what was the result? 
Positive (infected) .............  o 
Negative (not infected) .......  o 
Don’t know ........................  o 
THANKS FOR TAKING PART  
PLEASE PUT THE SALIVA AND QUESTIONNAIRE 
IN THE ENVELOPE  
4 
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Appendix 4 
Laboratory analysis of oral fluid specimens 
Each oral fluid specimen was tested for total IgG (to check specimen quality), anti-HIV, anti-
HBc and anti-HCV antibodies. 
• Anti-HIV testing was done using the Murex 1 + 2 GACELISA15,16 (VK61, Abbott 
Diagnostics, Maidenhead, UK), according to the manufacturer’s instructions, with 
positives confirmed using a modified protocol for the Clonesystems Detect-HIV FIA 
(Biostat Diagnostics, Stockport, UK). 
• Anti-HBc testing used Murex HBc ICE (Abbott Diagnostics, Maidenhead, UK), with 
positives confirmed with an ‘in-house’ RIA.17 
• Anti-HCV antibodies were sought employing a modified protocol for the Ortho HCV 
3.0 SAVe ELISA (Product number 940982, Ortho Diagnostics, Amersham, UK). 
Borderline reactives (OD/CO 0.8 – 3.0) were further investigated using a modified 
Chiron RIBA, HCV 3.0 (Product number 930780, Ortho Diagnostics, Amersham, 
UK). 
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Appendix 5 Frequency distribution of questionnaire responses among 
 committal prisoners by prison type and drug use  
Demographics and prison history 
 All 
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Age in years 15-17 
18-19 
20-24 
25-29 
30-34 
35-44 
45-54 
55-64 
65+ 
n 
mean 
median 
range 
74 (12.3) 
92 (15.2) 
172 (28.5) 
98 (16.2) 
62 (10.3) 
65 (10.8) 
35 (5.8) 
5 (0.8) 
1 (0.2) 
604 (100) 
26.3 
23 
15.73  
71 (14.9) 
77 (16.2) 
134 (28.2) 
77 (16.2) 
43 (9.1) 
44 (9.3) 
26 (5.5) 
3 (0.6) 
 
475 (100) 
25.5 
23 
15-63 
3 (2.3) 
15 (11.6) 
38 (29.5) 
21 (16.3) 
19 (14.7) 
21 (16.3) 
9 (7.0) 
2 (1.5) 
1 (0.8) 
129 (100) 
29.1 
26 
15-73 
12 (6.9) 
20 (11.6) 
74 (42.8) 
39 (22.5) 
17 (9.8) 
9 (5.2) 
2 (1.2) 
 
 
173 (100) 
24.5 
23 
16-54 
62 (14.5) 
72 (16.8) 
98 (22.9) 
58 (13.5) 
44 (10.3) 
56 (13.1) 
32 (7.5) 
5 (1.2) 
1 (0.2) 
428 (100) 
27.0 
23 
15-73 
Gender  Male
Female 
n 
564 (92.9) 
43 (7.1) 
607 (100) 
440 (92.0) 
38 (8.0) 
478 (100) 
124 (96.1) 
5 (3.9) 
129 (100) 
149 (85.1) 
26 (14.9) 
175 (100) 
412 (96.0) 
17 (4.0) 
429 (100) 
Current prison sentence Remand 
Sentence 
Warrant 
Extradition 
n 
315 (52.7) 
260 (43.5) 
22 (3.7) 
1 (0.2) 
598 (100) 
270 (57.2) 
196 (41.5) 
5 (1.1) 
1 (0.2) 
472 (100) 
45 (35.7) 
64 (50.8) 
17 (13.5) 
 
126 (100) 
107 (62.6) 
64 (37.4) 
 
 
171 (100) 
207 (48.6) 
196 (46.0) 
22 (5.2) 
1 (0.2) 
426 (100) 
Number of times 
imprisoned 
Never 
1-5 times 
more than 5 times 
n 
201 (33.4) 
274 (45.5) 
127 (21.1) 
602 (100) 
162 (34.0) 
212 (44.5) 
102 (21.4) 
476 (100) 
39 (30.7) 
63 (49.6) 
25 (19.7) 
127 (100) 
14 (8.1) 
93 (53.7) 
66 (38.1) 
173 (100) 
187 (43.6) 
181 (42.2) 
61 (14.2) 
429 (100) 
Time during the last 10 
yr. spent in prison 
None 
1 day-3 months 
>3-<12 months 
1-3 years 
>3 years 
n 
201 (38.0) 
66 (12.5) 
66 (12.5) 
108 (20.4) 
88 (16.6) 
529 (100) 
157 (37.5) 
54 (12.9) 
53 (12.6) 
84 (20.0) 
71 (17.0) 
419 (100) 
44 (40.0) 
12 (10.9) 
13 (11.8) 
24 (21.8) 
17 (15.5) 
110 (100) 
13 (8.2) 
16 (10.2) 
20 (12.6) 
51 (32.1) 
59 (37.1) 
159 (100) 
188 (50.8) 
50 (13.5) 
46 (12.4) 
57 (15.4) 
29 (7.8) 
370 (100) 
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Drug use 
 All 
n (%) 
High Medium 
n (%) n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
12 months 
Yes 
No 
n 
186 (30.8) 
604 (100) 
173 (36.3) 
304 (63.7) 
477 (100) 
13 (10.2) 
114 (89.8) 
Smoked heroin in the last 
418 (69.2) 
127 (100) 
146 (83.9) 
28 (16.1) 
174 (100) 
40 (9.3) 
389 (90.7) 
249 (100) 
Every injected drugs Yes 
No 
n 
175 (29.0) 
429 (71.0) 
604 (100) 
173 (36.2) 
305 (63.8) 
478 (100) 
2 (1.6) 
124 (98.4) 
126 (100) 
175 (100) 
 
 
0 
 
 
Age when first injected 
drugs 
10-13 
14-15 
16-17 
18-19 
20-24 
25-29 
30+ 
n 
mean 
median 
range 
7 (4.0) 
33 (18.9) 
45 (25.7) 
33 (18.9) 
39 (22.3) 
12 (6.9) 
6 (3.4) 
175 (100) 
18.8 
18  
10-52 
7 (4.0) 
32 (18.5) 
45 (26.0) 
33 (19.1) 
39 (22.5) 
11 (6.4) 
6 (3.5) 
173 (100) 
18.7 
18 
10-52 
0 
1 (50.0) 
0 
0 
0 
1 (50.0) 
0 
2 (100) 
20.5 
20.5 
15-26 
7 (4.0) 
33 (18.9) 
45 (25.7) 
33 (18.9) 
39 (22.3) 
12 (6.9) 
6 (3.4) 
175 (100) 
18.8 
18 
10-52 
0 
 
 
 
 
 
 
 
 
 
 
No of years since first 
injection 
<3 yrs 
3-5 yrs 
6-8 yrs 
9-14 yrs 
15+ 
n 
mean 
median 
range 
55 (31.8) 
49 (28.3) 
32 (18.5) 
25 (14.5) 
12 (6.9) 
173 (100) 
5.7 
4 
0-29 
54 (31.6) 
49 (28.7) 
32 (18.7) 
25 (14.5) 
11 (6.4) 
171 (100) 
5.7 
4 
0-29 
1 (50.0) 
0 
0 
0 
1 (50.0) 
2 (100) 
9.5 
9.5 
2-17 
55 (31.8) 
49 (28.3) 
32 (18.5) 
25 (14.5) 
12 (6.9) 
173 (100) 
5.7 
4 
0-29 
0 
 
 
 
 
 
 
 
 
Last time injected before 
coming into prison 
On the day committed 
In the week before 
In the month before 
In the year before 
More than one year before 
n 
73 (42.2) 
41 (23.7) 
15 (8.7) 
24 (13.9) 
20 (11.6) 
173 (100) 
73 (42.4) 
40 (23.3) 
15 (8.7) 
24 (14.5) 
19 (11.1) 
171 (100) 
0 
1 (50.0) 
0 
0 
1 (50.0) 
2 (100) 
73 (42.2) 
41 (23.7) 
15 (8.7) 
24 (13.9) 
20 (11.6) 
173 (100) 
0 
 
 
 
 
 
Started injecting in prison Yes 
No 
n 
30 (17.3) 
143 (82.7) 
173 (100) 
 29 (17.0) 
142 (83.0) 
171 (100) 
1 (50.0) 
1 (50.0) 
2 (100) 
30 (17.3) 
143 (82.7) 
173 (100) 
0 
 
 
On methadone prior to 
committal 
Yes 
No 
n 
63 (32.6) 
130 (67.4) 
193 (100) 
63 (33.0) 
128 (67.0) 
191 (100) 
0 (0.0) 
2 (100) 
2 (100) 
60 (34.7) 
113 (65.3) 
173 (100) 
3 (15) 
17 (85) 
20 (100) 
44 
Sharing equipment among injecting drug users 
 All 
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Sharing before        
Needles  Yes
No 
n 
53 (30.8) 
119 (69.2) 
172 (100) 
53 (31.2) 
117 (68.8) 
170 (100) 
0 (0.0) 
2 (100) 
2 (100) 
53 (30.8) 
119 (69.2) 
172 (100) 
0 
 
 
Syringes  Yes
No 
n 
57 (33.1) 
115 (66.9) 
172 (100) 
57 (33.5) 
113 (66.5) 
170 (100) 
0 (0.0) 
2 (100) 
2 (100) 
57 (33.1) 
115 (66.9) 
172 (100) 
0 
 
 
Filters and spoons etc Yes 
No 
n 
83 (48.8) 
87 (51.2) 
170 (100) 
83 (49.4) 
85 (50.6) 
168 (100) 
0 (0.0) 
2 (100) 
2 (100) 
83 (48.8) 
87 (51.2) 
170 (100) 
0 
 
 
Share before All 
Some 
None 
 
43 (24.9) 
50 (28.9) 
80 (46.2) 
173 (100) 
43 (25.2) 
50 (29.2) 
78 (45.6) 
171 (100) 
0 (0.0) 
0 (0.0) 
2 (100) 
2 (100) 
43 (24.9) 
50 (28.9) 
80 (46.2) 
173 (100) 
0 
 
 
 
Sharing inside        
Needles  Yes
No 
n 
64 (40.3) 
95 (59.7) 
159 (100) 
63 (40.1) 
94 (59.9) 
157 (100) 
1 (50.0) 
1 (50.0) 
2 (100) 
64 (40.3) 
95 (59.7) 
159 (100) 
0 
 
 
Syringes  Yes
No 
n 
69 (43.4) 
90 (56.6) 
159 (100) 
68 (43.3) 
89 (56.9) 
157 (100) 
1 (50.0) 
1 (50.0) 
2 (100) 
69 (43.4) 
90 (56.6) 
159 (100) 
0 
 
 
Filters and spoons etc. Yes 
No 
n 
67 (42.1) 
92 (57.9) 
159 (100) 
66 (42.0) 
91 (58.0) 
157 (100) 
1 (50.0) 
1 (50.0) 
2 (100) 
67 (42.1) 
92 (57.9) 
159 (100) 
0 
 
 
Share in All 
Some 
None 
 
62 (39.0) 
9 (5.7) 
88 (55.3) 
159 (100) 
61 (38.9) 
9 (5.7) 
87 (55.4) 
157 (100) 
1 (50.0) 
0 (0.0) 
1 (50.0) 
2 (100) 
62 (39.0) 
9 (5.7) 
88 (55.3) 
159 (100) 
0 
Times injected in the last 
months 
0 
1-19 
20+ 
n 
47 (27.8) 
35 (20.7) 
87 (51.5) 
169 (100) 
46 (27.5) 
35 (21.0) 
86 (51.5) 
167 (100) 
150.0 
0 (0.0) 
1 (50.0) 
2 (100) 
47 (27.8) 
35 (20.7) 
87 (51.5) 
169 (100) 
0 
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Sexual practices and precautions 
 All 
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Sexual intercourse with the 
opposite gender in the 12 
months prior to committal 
Yes 
No 
n 
539 (90.4) 
57 (9.6) 
596 (100) 
427 (91.0) 
42 (9.0) 
469 (100) 
112 (88.2) 
15 (11.8) 
127 (100) 
159 (93.0) 
12 (7.0) 
171 (100) 
380 (89.6) 
44 (10.4) 
424 (100) 
Number of heterosexual 
partners 
1-2 
3-9 
10+ 
n 
340 (63.4) 
149 (27.8) 
47 (8.8) 
536 (100) 
263 (62.0) 
124 (29.3) 
37 (8.7) 
424 (100) 
77 (68.8) 
25 (22.3) 
10 (8.9) 
112 (100) 
104 (66.2) 
43 (27.4) 
10 (6.4) 
157 (100) 
236 (62.2) 
106 (28.0) 
37 (9.8) 
379 (100) 
Use condoms during 
heterosexual intercourse 
Yes 
No 
n 
253 (47.6) 
278 (52.4) 
531 (100) 
201 (47.7) 
220 (52.3) 
421 (100) 
52 (47.3) 
58 (52.7) 
110 (100) 
64 (41.3) 
91 (58.7) 
155 (100)  
189 (50.3) 
187 (49.7) 
376 (100) 
Men ever have anal sex 
with men 
Yes 
No 
n 
9 (1.6) 
551 (98.4) 
560 (100) 
6 (1.4) 
433 (98.6) 
439 (100) 
3 (2.5) 
118 (97.5) 
121 (100) 
2 (1.4) 
146 (98.6) 
148 (100) 
7 (1.7) 
404 (98.3) 
411 (100) 
Use condoms during male 
homosexual intercourse 
Yes 
No 
n 
4 (50) 
4 (50) 
8 (100) 
3 (50) 
3 (50) 
6 (100) 
1 (50.0) 
1 (50.0) 
2 (100) 
1 (50) 
1 (50) 
2 (100) 
3 (50) 
3 (50) 
6 (100) 
Men ever have anal sex 
 with men in prison 
Yes 
No 
n 
3 (0.9) 
351 (99.1) 
354 (100) 
1 (0.3) 
275 (99.6) 
276 (100) 
2 (25.6) 
76 (97.4) 
78 (100) 
1 (0.8) 
130 (99.2) 
131 (100) 
2 (0.9) 
220 (99.1) 
222 (100) 
Paid for any type of sex Yes 
No 
n 
26 (4.6) 
533 (95.3) 
559 (100) 
24 (5.5) 
414 (94.5) 
438 (100) 
2 (1.7) 
119 (98.3) 
121 (100) 
8 (5.4) 
140 (94.6) 
148 (100) 
18 (4.4) 
392 (95.6) 
410 (100) 
Been paid for any type of 
sex 
Yes 
No 
n 
15 (2.5) 
586 (97.5) 
601 (100) 
15 (3.2) 
460 (96.8) 
475 (100) 
0 (0.0) 
126 (100) 
126 (100) 
12 (7) 
159 (93.0) 
171 (100) 
3 (0.7) 
426 (99.3) 
429 (100) 
Ever treated for STI Yes 
No 
n 
44 (7.3) 
556 (92.7) 
600 (100) 
42 (8.9) 
432 (91.1) 
474 (100) 
2 (1.6) 
124 (98.4) 
126 (100) 
27 (15.8) 
144 (84.2) 
171 (100) 
17 (4.0) 
411 (96.0) 
428 (100) 
Tattooing       
Tattoo  Yes
No 
n 
358 (59.4) 
245 (40.6) 
603 (100) 
278 (58.3) 
199 (41.7) 
478 (100) 
80 (63.0) 
47 (37.0) 
127 (100) 
139 (79.9) 
35 (20.1) 
174 (100) 
219 (51.0) 
210 (49.0) 
429 (100) 
Tattoo in prison Yes 
No 
n 
89 (25.0) 
267 (75.0) 
356 (100) 
70 (25.4) 
206 (74.6) 
276 (100) 
19 (23.7) 
61 (76.3) 
80 (100) 
42 (30.2) 
97 (69.8) 
139 (100) 
47 (21.7) 
170 (78.3) 
217 (100) 
Tattoo done by Self 
Friend 
Artist 
n 
109 (30.8) 
112 (31.6) 
133 (37.6) 
354 (100) 
93 (33.8) 
82 (29.8) 
100 (36.4) 
275 (100) 
16 (20.2) 
30 (38.0) 
33 (41.8) 
79 (100) 
55 (39.6) 
43 (30.9) 
41 (29.5) 
139 (100) 
54 (25.1) 
69 (32.1) 
92 (42.8) 
215 (100) 
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Reported blood test results and vaccination coverage 
 All 
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Ever have a blood test for 
HIV 
Yes 
No 
Don’t know 
n 
172 (28.4) 
425 (70.2) 
8 (1.3) 
605 (100) 
154 (32.2) 
319 (66.7) 
5 (1.1) 
478 (100) 
18 (14.2) 
106 (83.5) 
3 (2.3) 
127 (100) 
116 (66.3) 
58 (33.1) 
1 (0.6) 
175 (100) 
56 (13.1) 
366 (85.3) 
7 (1.6) 
429 (100) 
Reported HIV result Yes 
No 
Don’t know 
n 
11 (6.5) 
126 (74.1) 
33 (19.4) 
170 (100) 
9 (5.9) 
115 (75.7) 
28 (18.4) 
152 (100) 
2 (11.1) 
11 (61.1) 
5 (27.8) 
18 (100) 
10 (8.8) 
80 (70.2) 
24 (21.0) 
114 (100) 
1 (1.8) 
46 (82.1) 
9 (16.1) 
56 (100) 
Ever have a blood test for 
hepatitis B 
Yes 
No 
Don’t know 
n 
123 (20.4) 
450 (74.5) 
31 (5.1) 
604 (100) 
112 (23.5) 
343 (71.9) 
22 (4.6) 
477 (100) 
11 (8.7) 
107 (84.3) 
9 (7.1) 
127 (100) 
100 (57.1) 
67 (38.3) 
8 (4.6) 
175 (100) 
23 (5.4) 
382 (89.2) 
23 (5.4) 
428 (100) 
Reported hepatitis B 
result 
Yes 
No 
Don’t know 
n 
21 (17.3) 
84 (69.4) 
16 (13.2) 
121 (100) 
19 (17.1) 
78 (70.3) 
14 (12.6) 
111 (100) 
2 (20.0) 
6 (60.0) 
2 (20.0) 
10 (100) 
20 (20.2) 
67 (67.7) 
12 (12.1) 
99 (100) 
1 (4.5) 
17 (77.3) 
4 (18.2) 
22 (100) 
Ever have a blood test for 
hepatitis C 
Yes 
No 
Don’t know 
n 
132 (21.8) 
448 (74.0) 
25 (4.1) 
605 (100) 
128 (26.8) 
333 (69.7) 
17 (3.5) 
478 (100) 
4 (3.1) 
115 (90.6) 
8 (6.3) 
127 (100) 
115 (65.7) 
55 (31.4) 
5 (2.9) 
175 (100) 
17 (4.0) 
392 (91.3) 
20 (4.7) 
429 (100) 
Reported hepatitis C 
result 
Yes 
No 
Don’t know 
n 
89 (69.0) 
25 (19.4) 
15 (11.6) 
129 (100) 
88 (70.4) 
22 (17.6) 
15 (12.0) 
125 (100) 
1 (25.1) 
3 (75.0) 
0 (0.0) 
4 (100) 
88 (77.9) 
14 (12.4) 
11 (9.7) 
113 (100) 
1 (6.3) 
11 (68.7) 
4 (25.0) 
16 (100) 
Vaccinated against 
hepatitis B 
Yes 
No 
Don’t know 
n 
121 (20.1) 
442 (73.3) 
40 (6.6) 
603 (100) 
113 (23.7) 
342 (71.9) 
21 (4.4) 
476 (100) 
8 (6.3) 
100 (78.7) 
19 (15.0) 
127 (100) 
79 (45.4) 
93 (53.4) 
2 (1.2) 
174 (100) 
42 (9.8) 
348 (81.3) 
38 (8.9) 
428 (100) 
Vaccinated in prison Yes 
No 
n 
91 (79.1) 
24 (20.9) 
115 (100) 
87 (79.1) 
23 (20.9) 
110 (100) 
4 (80.0) 
1 (20.0) 
5 (100) 
61 (80.3) 
15 (19.7) 
76 (100) 
30 (76.9) 
9 (23.1) 
39 (100) 
Complete 3 doses of 
hepatitis B  vaccine 
Yes 
No 
Don’t know 
n 
55 (47.4) 
51 (44.0) 
10 (8.6) 
116 (100) 
52 (47.3) 
48 (43.6) 
10 (9.1) 
110 (100) 
3 (50.0) 
3 (50.0) 
0 (100) 
6 (100) 
41 (53.2) 
31 (40.3) 
5 (6.5) 
77 (100) 
14 (35.9) 
20 (51.3) 
5 (12.8) 
39 (100) 
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Oral fluid test results 
 All 
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Test HIV positive Yes 
No 
n 
12 (2.0) 
584 (98.0) 
596 (100) 
10 (2.1) 
463 (97.9) 
473 (100) 
2 (1.6) 
121 (98.4) 
123 (100) 
10 (5.8) 
163 (94.2) 
173 (100) 
2 (0.5) 
418 (99.5) 
420 (100) 
Test hepatitis B positive Yes 
No 
n 
37 (6.2) 
559 (93.8) 
596 (100) 
35 (7.4) 
438 (92.6) 
473 (100) 
2 (1.6) 
121 (98.4) 
123 (100) 
31 (17.9) 
142 (82.1) 
173 (100) 
5 (1.2) 
415 (98.8) 
420 (100) 
Test hepatitis C positive Yes 
No 
n 
130 (21.8) 
446 (78.2) 
596 (100) 
129 (27.3)) 
344 (72.7) 
473 (100) 
1 (0.8) 
122 (99.2) 
123 (100) 
124 (71.7) 
49 (28.3) 
173 (100) 
6 (1.4) 
414 (98.6) 
420 (100) 
Prison details       
Prison   St Patricks
Cork 
Limerick Male 
Mountjoy 
Mountjoy Female 
n 
151 (24.9) 
84 (13.8) 
45 (7.4) 
289 (47.6) 
38 (6.3) 
607 (100) 
151 (31.6) 
 
 
289 (60.5) 
38 (7.9) 
478 (100) 
 
84 (65.1) 
45 (34.9) 
 
 
129 (100) 
34 (19.4) 
1 (0.6) 
1 (0.6) 
113 (64.6) 
26 (14.8) 
175 (100) 
117 (27.3) 
80 (18.6) 
44 (10.2) 
176 (41.0) 
12 (2.8) 
429 (100) 
Risk  High
Medium 
n 
478 (78.7) 
129 (21.2) 
607 (100) 
478 (100) 
 
 
 
129 (100) 
 
173 (98.9) 
2 (1.1) 
175 (100) 
305 (71.1) 
124 (28.9) 
429 (100) 
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Appendix 6 Frequency distributions of questionnaire responses in the census 
 survey by prison type and injecting drug use  
Demographics and prison history 
 All 
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Age in years 16-17 
18-19 
20-24 
25-29 
30-34 
35-44 
45-54 
55-64 
65+ 
n 
40 (3.5) 
137 (11.9) 
369 (32.1) 
255 (22.2) 
151 (13.2) 
135 (11.8) 
45 (3.9) 
14 (1.2) 
1 (0.9) 
1147 (100) 
28 (4.1) 
94 (13.8) 
219 (32.2) 
145 (21.3) 
91 (13.4) 
78 (11.5) 
17 (2.5) 
7 (1) 
1 (0.2) 
680 (100) 
12 (2.6) 
43 (9.2) 
150 (32.1) 
110 (23.6) 
60 (12.8) 
57 (12.2) 
28 (6) 
7 (1.5) 
0 
467 (100) 
10 (2) 
59 (12.1) 
192 (39.3) 
123 (25.1) 
63 (12.9) 
39 (8) 
2 (0.4) 
1 (0.2) 
0 
489 (100) 
29 (4.5) 
77 (11.9) 
170 (26.3) 
130 (20.1) 
87 (13.5) 
95 (14.7) 
43 (6.6) 
13 (2) 
1 (0.2) 
645 (100) 
Gender  Male
Female 
n 
1148 (95.2) 
57 (4.7) 
1205 (100) 
667 (93) 
50 (7) 
717 (100) 
481 (98.6) 
7 (1.4) 
488 (100) 
480 (93.4) 
34 (6.6) 
514 (100) 
651 (96.6) 
23 (3.4) 
674 (100) 
Length of prison 
sentence 
Remand 
3 months or less 
> 3-<12 months 
1-3 years 
>3 years 
n 
157 (13.1) 
60 (5) 
213 (17.8) 
308 (25.8) 
458 (38.3) 
1196 (100) 
120 (16.9) 
29 (4.1) 
111 (15.6) 
170 (23.9) 
281 (39.5) 
711 (100) 
37 (7.6) 
31 (6.4) 
102 (21) 
138 (28.5) 
177 (36.5) 
485 (100) 
65 (12.7) 
18 (3.5) 
66 (12.9) 
124 (24.3) 
238 (46.6) 
511 (100) 
92 (13.7) 
40 (5.9) 
144 (21.4) 
179 (26.6) 
218 (32.4) 
673 (100) 
Length in prison on 
this sentence 
3 months or less 
> 3-<12 months 
1-3 years 
>3 years 
n 
319 (27) 
392 (33.2) 
319 (27) 
151 (12.8) 
1181 (100) 
201 (28.5) 
223 (31.6) 
195 (27.7) 
86 (12.2) 
705 (100) 
118 (24.8) 
169 (35.5) 
124 (26) 
65 (13.7) 
476 (100) 
119 (23.3) 
154 (30.2) 
164 (32.2) 
73 (14.3) 
510 (100) 
198 (30) 
232 (35.2) 
152 (23) 
78 (11.8) 
660 (100) 
Time during the last 
10 yr. spent in prison 
3 months or less 
> 3-<12 months 
1-3 years 
>3 years 
n 
137 (11.6) 
197 (16.7) 
300 (25.4) 
546 (46.3) 
1180 (100) 
87 (12.3) 
103 (14.6) 
167 (23.7) 
349 (49.4) 
706 (100) 
50 (10.5) 
94 (19.8) 
133 (28.1) 
197 (41.6) 
474 (100) 
40 (7.8) 
49 (9.6) 
121 (23.7) 
300 (58.8) 
510 (100) 
97 (14.7) 
146 (22.1) 
175 (26.5) 
242 (36.7) 
660 (100) 
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Drug use 
 All 
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Smoked heroin in the last 
12 months 
Yes 
No 
n 
545 (45.9) 
642 (54.1) 
1187 (100) 
408 (57.4) 
303 (42.6) 
711 
137 (28.8) 
339 (71.2) 
476 
420 (82.5) 
89 (17.5) 
509 (100) 
121 (18.1) 
549 (81.9) 
670 (100) 
Every injected drugs Yes 
No 
n 
514 (43.2) 
674 (56.7) 
1188 (100) 
414 (58.2) 
297 (41.8) 
711 (100) 
100 (21) 
377 (79) 
477 (100) 
514 (100) 
 
 
 
674 (100) 
 
Age when first injected 
drugs 
11-13 
14-15 
16-17 
18-19 
20-24 
25-29 
30-38 
n 
25 (5) 
97 (19.6) 
144 (29) 
93 (18.8) 
91 (18.4) 
31 (6.3) 
14 (2.8) 
495 (100) 
22 (5.4) 
78 (19.3) 
118 (29.2) 
79 (19.5) 
68 (16.8) 
28 (6.9) 
11 (2.7) 
404 (100) 
3 (3.3) 
19 (20.9) 
26 (28.6) 
14 (15.4) 
23 (25.3) 
3 (3.3) 
3 (3.3) 
91 (100) 
25 (5) 
97 (19.6) 
144 (29) 
93 (18.8) 
91 (18.4) 
31 (6.3) 
14 (2.8) 
495 (100) 
0 
 
 
 
 
 
 
 
No of years since first 
injection 
<3 yrs 
3-5 yrs 
6-8 yrs 
9-14 yrs 
15+ 
 
85 (18) 
153 (32.3) 
110 (23.2) 
72 (15.2) 
53 (11.2) 
473 (100) 
68 (17.7) 
127 (33) 
98 (25.4) 
55 (14.3) 
37 (9.6) 
385 (100) 
17 (19.3) 
26 (29.5) 
12 (13.6) 
17 (19.3) 
16 (18.2) 
88 (100) 
85 (18) 
153 (32.3) 
110 (23.2) 
72 (15.2) 
53 (11.2) 
473 (100) 
0 
 
 
 
 
 
Last time injected before 
coming into prison 
On the day committed 
In the week before 
In the month before 
In the year before 
More than one year 
before 
Does not apply 
n 
261 (52.3) 
86 (17.2) 
34 (6.8) 
43 (8.6) 
43 (8.6) 
 
32 (6.4) 
499 (100) 
220 (54) 
69 (16.9) 
29 (7.1) 
30 (7.4) 
35 (8.6) 
 
24 (5.9) 
407 (100) 
41 (44) 
17 (18.3) 
5 (5.4) 
13 (14) 
8 (8.6) 
 
9 (97) 
93 (100) 
261 (52.3) 
86 (17.2) 
34 (6.8) 
43 (8.6) 
43 (8.6) 
 
32 (6.4) 
499 (100) 
0 
 
 
 
 
 
 
 
Started injecting in 
prison 
Yes 
No 
n 
104 (20.5) 
402 (79.5) 
506 (100) 
82 (20) 
329 (80) 
411 (100) 
22 (23.2) 
73 (76.8) 
95 (100) 
104 (20.5) 
402 (79.5) 
506 (100) 
0 
 
 
On methadone prior to 
committal 
Yes 
No 
n 
187 (37.3) 
315 (62.7) 
502 (100) 
156 (38.3) 
253 (61.7) 
409 (100) 
31 (33.3) 
62 (66.7) 
93 (100) 
187 (37.3) 
315 (62.7) 
502 (100) 
0 
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Sharing equipment among injecting drug users 
 All 
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Sharing before        
Needles  Yes
No 
n 
225 (46) 
264 (54) 
489 (100) 
184 (46.1) 
215 (53.8) 
399 (100) 
41 (45.6) 
49 (54.4) 
90 (100) 
225 (46) 
264 (54) 
489 (100) 
0 
 
 
Syringes  Yes
No 
n 
232 (51.4) 
219 (48.6) 
451 (100) 
192 (51.9) 
178 (48.1) 
370 (100) 
40 (49.4) 
41 (50.6) 
81 (100) 
232 (51.4) 
219 (48.6) 
451 
0 
 
 
Filters and spoons etc Yes 
No 
n 
263 (58.6) 
186 (41.4) 
449 (100) 
220 (60) 
147 (40) 
367 (100) 
43 (52.4) 
39 (47.6) 
82 
263 (58.6) 
186 (41.4) 
449 (100) 
0 
 
 
Share before All 
Some 
Zero 
 
 
175 (35.1) 
140 (28) 
184 (36.9) 
499 (100) 
 
144 (36.9) 
117 (30) 
129 (33.1) 
390 (100) 
 
31 (35.2) 
23 (26.1) 
34 (38.6) 
88 (100) 
 
175 (36.6) 
140 (29.3) 
163 (34.1) 
478 (100) 
 
 
Sharing inside        
Needles  Yes
No 
n 
351 (70.6) 
146 (29.4) 
497 (100) 
295 (72.5) 
112 (27.5) 
407 (100) 
56 (62.2) 
34 (37.8) 
90 (100) 
351 (70.6) 
146 (29.4) 
497 (100) 
0 
 
 
Syringes  Yes
No 
n 
335 (72.2) 
129 (27.8) 
464 (100) 
283 (73.9) 
100 (26.1) 
383 (100) 
52 (64.2) 
29 (35.8) 
81 (100) 
334 (72.1) 
129 (27.9) 
463 (100) 
0 
 
 
Filters and spoons etc. Yes 
No 
n 
304 (67.4) 
147 (32.6) 
451 (100) 
255 (68.7) 
116 (31.3) 
371 (100) 
49 (61.2) 
31 (38.8) 
80 (100) 
304 (67.4) 
147 (32.6) 
451 (100) 
0 
 
 
Share in All 
Some 
Zero 
 
285 (56.5) 
87 (17.3) 
120 (26.1) 
504 (100) 
241 (59.8) 
69 (17.1) 
93 (23.1) 
403 (100) 
44 (49.4) 
18 (20.2) 
27 (30.3) 
89 (100) 
285 (58) 
86 (17.5) 
120 (24.4) 
491 (100) 
 
 
 
 
Times injected in the last 
month 
0 
1-19 
20+ 
n 
221 (50.5) 
141 (32.2) 
76 (17.3) 
438 (100) 
154 (42.9) 
133 (37) 
72 (20.1) 
359 (100) 
67 (84.8) 
8 (10.1) 
4 (5.1) 
79 (100) 
221 (50.5) 
141 (32.2) 
76 (17.3) 
438 (100) 
0 
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Sexual practices and precautions 
 All 
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Sexual intercourse 
with the opposite 
gender in the 12 
months prior to 
committal 
Yes 
No 
n 
 
 
1088 (92) 
94 (8) 
1182 (100) 
 
 
662 (93.1) 
49 (6.9) 
711 (100) 
 
 
426 (90.4) 
45 (9.6) 
471 (100) 
 
 
483 (94.5) 
28 (5.5) 
511 (100) 
 
 
596 (90.2) 
65 (9.8) 
661 (100) 
 
 
Use condoms during 
heterosexual 
intercourse 
 
Yes 
No 
n 
 
347 (33.8) 
679 (66.2) 
1026 (100) 
 
211 (33.9) 
412 (66.1) 
623 (100) 
 
136 (33.7) 
267 (66.2) 
403 (100) 
 
138 (30.6) 
313 (69.4) 
451 (100) 
 
205 (36.2) 
361 (63.8) 
566 (100) 
 
Men ever have anal 
sex with men 
Yes 
No 
n 
28 (2.5) 
1088 (97.5) 
1116 (100) 
14 (2.1) 
639 (97.9) 
653 (100) 
14 (3) 
449 (97) 
463 (100) 
15 (3.4) 
459 (96.6) 
474 (100) 
12 (1.9) 
621 (98.1) 
633 (100) 
Use condoms during male 
homosexual 
intercourse 
Yes 
No 
n 
4 (19) 
17 (81) 
21 (100) 
3 (27.3) 
8 (72.7) 
11 (100) 
1 (10) 
9 (90) 
10 (100) 
1 (7.1) 
13 (92.9) 
14 (100) 
3 (42.9) 
4 (57.1) 
7 (100) 
Men ever have anal 
sex with men in 
prison 
Yes 
No 
n 
20 (1.8) 
1067 (98.2) 
1087 (100) 
7 (1.1) 
629 (98.9) 
636 (100) 
13 (2.9) 
438 (97.1) 
451 (100) 
9 (2) 
455 (98) 
464 (100) 
10 (1.6) 
605 (98.5) 
615 (100) 
Ever treated for STD Yes 
No 
n 
147 (12.6) 
1018 (87.4) 
1165 (100) 
103 (14.6) 
600 (85.4) 
703 (100) 
44 (9.5) 
418 (90.5) 
462 (100) 
87 (17.3) 
416 (82.7) 
503 (100) 
60 (9.2) 
593 (90.8) 
653 (100) 
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Reported blood test results and vaccination coverage 
 All 
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Ever have a blood test for 
HIV 
Yes 
No 
Don’t know 
n 
449 (37.8) 
703 (59.3) 
34 (2.9) 
1186 (100) 
328 (46.2) 
366 (51.5) 
16 (2.2) 
710 (100) 
121 (25.4) 
337 (70.8) 
18 (3.8) 
476 (100) 
332 (65) 
172 (33.6) 
7 (1.4) 
511 (100) 
116 (17.4) 
524 (78.8) 
25 (3.8) 
665 (100) 
Reported HIV result Yes 
No 
Don’t know 
n 
20 (4.5) 
370 (83.5) 
53 (12) 
443 (100) 
16 (4.9) 
269 (82.8) 
40 (12.3) 
325 (100) 
4 (3.4) 
101 (85.6) 
13 (11) 
118 (100) 
18 (5.5) 
274 (83.8) 
35 (10.7) 
327 (100) 
2 (1.7) 
95 (82.6) 
18 (15.7) 
115 (100) 
Ever have a blood test 
for hepatitis B 
Yes 
No 
Don’t know 
n 
335 (28.5) 
773 (65.7) 
69 (5.9) 
1177 (100) 
260 (36.8) 
411 (58.1) 
36 (5.1) 
707 (100) 
75 (16) 
362 (77) 
33 (7) 
470 (100) 
252 (49.6) 
231 (45.5) 
25 (4.9) 
508 (100) 
83 (12.6) 
534 (80.9) 
43 (6.5) 
660 (100) 
Reported hepatitis B 
result 
Yes 
No 
Don’t know 
n 
 
63 (19.6) 
209 (64.9) 
50 (15.5) 
322 (100) 
48 (19.2) 
164 (65.6) 
38 (15.2) 
250 (100) 
15 (20.8) 
45 (62.5) 
12 (1.7) 
72 (100) 
58 (24) 
152 (62.8) 
32 (13.2) 
242 (100) 
5 (6.3) 
57 (71.2) 
18 (22.5) 
80 (100) 
Ever have a blood test 
for hepatitis C 
Yes 
No 
Don’t know 
n 
348 (29.9) 
725 (62.3) 
91 (7.8) 
1164 (100) 
278 (39.6) 
382 (54.4) 
42 (6) 
702 (100) 
70 (15.2) 
343 (74.2) 
49 (10.6) 
462 (100) 
302 (59.3) 
188 (36.9) 
19 (3.7) 
509 (100) 
46 (7.1) 
530 (81.9) 
71 (11) 
647 (100) 
Reported hepatitis C 
result 
Yes 
No 
Don’t know 
n 
232 (67.8) 
76 (22.2) 
34 (9.9) 
342 (100) 
189 (69.5) 
56 (20.6) 
27 (9.9) 
272 (100) 
43 (61.4) 
20 (25.6) 
7 (10) 
70 (100) 
229 (76.6) 
44 (14.7) 
26 (8.7) 
299 (100) 
3 (7) 
32 (74.4) 
8 (18.6) 
43 (100) 
Vaccinated against 
hepatitis B 
Yes 
No 
Don’t know 
n 
504 (43.5) 
547 (47.1) 
109 (9.4) 
1160 (100) 
381 (54.7) 
272 (39) 
44 (6.3) 
697 (100) 
123 (26.6) 
275 (59.4) 
65 (14) 
463 (100) 
300 (59.6) 
180 (35.8) 
23 (4.6) 
503 (100) 
202 (31.2) 
361 (55.7) 
85 (13.1) 
648 (100) 
Vaccinated in prison Yes 
No 
n 
446 (90.8) 
45 (9.2) 
491 (100) 
334 (90.5) 
35 (9.5) 
369 (100) 
112 (91.8) 
10 (8.2) 
122 (100) 
266 (91.1) 
26 (8.9) 
292 (100) 
179 (90.9) 
18 (9.1) 
197 (100) 
Complete 3 doses of 
hepatitis B vaccine 
Yes 
No 
Don’t know 
n 
304 (60.4) 
180 (35.8) 
19 (3.8) 
503 (100) 
230 (61.2) 
132 (35.1) 
14 (3.7) 
376 (100) 
74 (58.3) 
48 (37.8) 
5 (3.9) 
127 (100) 
184 (61.7) 
101 (33.9) 
13 (4.4) 
298 (100) 
118 (58) 
79 (39) 
6 (3) 
203 (100) 
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Oral fluid test results 
 All 
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Test HIV positive Yes 
No 
n 
24 (2) 
1169 (98) 
1193 (100) 
20 (2.8) 
693 (97.2) 
713 (100) 
4 (0.8) 
476 (99.2) 
480 (100) 
18 (3.5) 
491 (96.5) 
509 (100) 
6 (0.9) 
663 (99.1) 
669 (100) 
Test hepatitis B 
positive 
Yes 
No 
n 
104 (8.7) 
1089 (91.3) 
1193 (100) 
87 (12.2) 
626 (87.8) 
713 (100) 
17 (3.5) 
463 (96.5) 
480 (100) 
94 (18.5) 
415 (81.5) 
509 (100) 
10 (1.5) 
659 (98.5) 
669 (100) 
Test hepatitis C  
positive 
Yes 
No 
n 
442 (37) 
751 (63) 
1193 (100) 
363 (50.9) 
350 (49.1) 
713 (100) 
79 (16.5) 
401 (83.5) 
480 (100) 
414 (81.3) 
95 (18.7) 
509 (100) 
25 (3.7) 
644 (96.3) 
669 (100) 
Prison details       
Prison   Limerick Female
Mountjoy Female 
Portlaoise 
Shelton Abbey 
St Patricks 
Mountjoy Training 
Cork 
Limerick Male 
Mountjoy 
Wheat Field 
n 
7 (0.6) 
50 (4.1) 
80 (6.6) 
38 (3.2) 
88 (7.3) 
77 (6.4) 
228 (18.9) 
135 (11.2) 
359 (29.8) 
143 (11.9) 
1205 (100) 
 
50 (7) 
 
 
88 (12.3) 
77 (10.7) 
 
 
359 (50.1) 
143 (19.9) 
717 (100) 
7 (1.4) 
 
80 (16.3) 
38 (7.8) 
 
 
228 (46.7) 
135 (27.7) 
 
 
488 (100) 
2 (0.4) 
32 (6.2) 
33 (6.4) 
10 (2) 
44 (8.6) 
36 (7) 
37 (7.2) 
18 (3.5) 
222 (43.2) 
80 (15.5) 
514 (100) 
5 (0.7) 
18 (2.7) 
47 (7) 
24 (3.6) 
43 (6.4) 
40 (5.9) 
187 (27.7) 
114 (16.9) 
136 (20.2) 
60 (8.9) 
674 (100) 
Risk  High
Medium 
n 
717 (59.5) 
488 (40.5) 
1205 (100) 
717 (100) 
 
 
 
488 (100) 
 
414 (80.5) 
100 (19.5) 
514 (100) 
297 (44.1) 
377 (55.9) 
674 (100) 
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Appendix 7 
Reported sexual risk factors for each infection 
7A – Reported sexual behaviour and risk factors for hepatitis B in committal prisoners 
 Hepatitis B 
Positive Negative 
No./Total (%) No./Total (%) 
Test of association 
Use condoms during heterosexual 
intercourse 
12/32 (37.5) 236/492 (48.0) Pearson X2 = 1.3, df = 1, p = 0.25 
NS 
Number of heterosexual 1-2 
partners in the last 3-9 
year 10+ 
22/32 (68.7) 313/496 (63.1) 
6/32 (18.7) 141/496 (28.4) 
4/32 (12.5) 42/496 (8.5) 
Fisher’s exact test p = 0.09 
NS 
Men ever have anal sex with men 0/28 (0.0) 9/524 (1.7) Fisher’s exact test p = 1.0 
NS 
Men ever have anal sex with men in 
prison 
0/24 (0.) 2/235 (0.6) Fisher’s exact test p = 1.0 
NS 
Ever paid for any type of sex 1/28 (3.6) 25/523 (4.8) Fisher’s exact test p = 1.0 
NS 
Ever been paid for any type of sex 4/35 (11.4) 11/556 (2.0) Respondents who tested positive for 
hepatitis B were more likely to report 
having been paid for sex 
Fisher’s exact test p = 0.009 
Ever treated for STI* 8/35 (22.8) 36/555 (6.5) Respondents who tested positive for 
hepatitis B were more likely to report 
having treated for STI 
Pearson X2 = 12.8, df = 1, p = 0.0003 
*Sexually transmitted infection 
NS = Not significant 
7B – Reported sexual behaviour and risk factors for hepatitis C in committal prisoners 
 Hepatitis C 
Positive Negative 
No./Total (%) No./Total (%) 
Test of association 
Use condoms during heterosexual 
intercourse 
45/117 (38.5) 203/407 (49.9) Respondents who tested positive for 
hepatitis C were more likely to 
report using condoms during 
heterosexual intercourse 
Pearson X2 = 4.7, df = 1, p = 0.03 
Number of heterosexual 1-2 
partners in the last 3-9 
year 10+ 
76/119 (63.8) 259/409 (63.3) 
33/119 (27.7) 114/409 (27.9) 
10/119 (8.4) 36/409 (8.8) 
Pearson X2 = 0.0, df = 1, p = 0.99 
Men ever have anal sex with men 0/107 (0.0) 9/445 (2.0) Fisher’s exact test p = 0.2 
NS 
Men ever have anal sex with men in 
prison 
0/100 (0.0) 2/249 (0.8) Fisher’s exact test p = 1.0 
NS 
Ever paid for any type of sex 8/107 (7.5) 18/444 (4.0) Fisher’s exact test p = 1.0 
NS 
Ever been paid for any type of sex 9/127 (7.1) 6/464 (1.3) Respondents who tested positive for 
hepatitis C were more likely to 
report having been paid for sex 
Pearson X2 = 13.5, df = 0.0002 
Ever treated for STI* 26/127 (20.5) 18/463 (3.9) Respondents who tested positive for 
hepatitis C were more likely to 
report having treated for STI 
Pearson X2 =39.7, df = 1, p <0.0001 
NS 
*Sexually transmitted infection 
NS = Not significant 
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7C – Reported sexual behaviour and risk factors for HIV in committal prisoners 
 HIV 
Positive Negative 
No./Total (%) No./Total (%) 
Test of association 
Use condoms during heterosexual 
intercourse 
5/11 (45.4) 243/513 (47.4) Pearson X2 = 0.0, df = 1, p = 0.9 
NS 
Number of heterosexual 1-2 
partners in the last 3-9 
year 10+ 
7/12 (58.3) 328/516 (63.6) 
4/12 (33.3) 143/516 (27.7) 
1/12 (8.3) 45/516 (8.7) 
Fisher’s exact test p = 0.9 
NS 
Men ever have anal sex with men 0/8 (0.0) 9/544 (1.6) Fisher’s exact test p = 1.0 
NS 
Men ever have anal sex with men in 
prison 
0/6 (0.0) 2/343 (0.6) Fisher’s exact test p = 1.0 
NS 
Ever paid for any type of sex 0/8 (0.0) 26/543 (4.8) Fisher’s exact test p = 0.6 
NS 
Ever been paid for any type of sex 212 (16.7) 13/579 (2.2) Respondents who tested positive 
for hepatitis HIV were more likely 
to report having been paid for sex 
Fisher’s exact test p = 0.03 
Ever treated for STI* 1/12 (8.3) 43/578 (7.4) Fisher’s exact test p = 0.6 
NS 
*Sexually transmitted infection 
NS = Not significant 
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Appendix 8 
Logistic regression models to identify the determinates 
of each infection in the drug using population 
8A – Logistic regression model to identify independence association with hepatitis B infection among 
injecting drug users in the committal survey 
 Total 
sample 
173 
No. 
Hepatitis B 
negative 
142 
No. 
Hepatitis B 
positive 
31 
No. 
Prevalence of 
hepatitis B 
 
% 
Odds 
ratio 
95% CI p-value 
Age 
<30 yrs 
>30 yrs 
Missing 
 
143 
28 
2 
 
122 
19 
 
 
21 
9 
 
 
14.7 
32.1 
 
 
1 
4.8 
 
 
 
1.6-14.1 
 
 
 
0.004 
 
No. of 
heterosexual 
partners in the 
last year 
1-2 
3-10 
10+ 
Missing 
 
 
 
 
103 
42 
10 
18 
 
 
 
 
86 
36 
6 
 
 
 
 
 
17 
6 
4 
 
 
 
 
 
16.5 
14.3 
40 
 
 
 
 
 
1 
1.1 
5.3 
 
 
 
 
 
0.4-3.2 
1.2-22.3 
 
 
 
 
0.84 
0.02 
Whole model X2 = 11.2 R2 = .8 p = 0.0107 
 
8B – Logistic regression model to identify independence association with hepatitis C infection among 
injecting drug users in the committal survey 
 Total 
sample 
173 
No. 
Hepatitis C 
negative 
49 
No. 
Hepatitis C 
positive 
124 
No. 
Prevalence of 
hepatitis C 
 
% 
Odds 
ratio 
95% CI p-value 
Time injected in 
the last month 
0 
1-19 
20+ 
Missing 
 
 
48 
35 
85 
4 
 
 
24 
11 
13 
 
 
 
24 
24 
72 
 
 
 
50.0 
68.6 
84.7 
 
 
 
1 
2.9 
5.9 
 
 
 
1.0-8.9 
2.4-15.8 
 
 
 
0.0525 
0.0002 
 
Shared needles in 
prison 
No 
Yes 
Missing 
 
 
102 
63 
8 
 
 
40 
5 
 
 
 
62 
58 
 
 
 
60.8 
92.1 
 
 
 
1 
5.9 
 
 
 
 
2.2-18.8 
 
 
 
0.0009 
Whole model X2 = 31.6 R2 = .18 p < 0.001 
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Appendix 9 
Methods employed to estimate the total numbers of cases. 
All the low risk prisons were excluded from the survey. It may be assumed that the 
prevalence of the three infections among prisoners in the low risk prisons would be higher 
than the national community prevalence but lower than the prevalence in non-drug users in 
medium risk prisons. These prevalence rates can be used to estimate prevalence in the low 
risk prisons. 
National prevalence: 
• The national population prevalence for hepatitis B, based on a postal survey in 18 
District Electoral Divisions using a multi-stage stratified cluster sampling technique, 
was 0.51% (95% CI 0.0-1.8).18 The required sample size was based on an expected 
prevalence of 1% + 0.5% in the survey population (n = 2,640, the response rate was 
60.4% (1,793)). The author acknowledged that as this population was selected from the 
electoral register, on average 14% of those eligible had not registered to vote. The 
registered population is likely to under-represent the high risk drug users. 
• There is no national prevalence estimate available for hepatitis C. 
• The Irish population prevalence for HIV, based on unlinked anonymous tests in 
antenatal women, was 0.02%.19 This is a cumulative prevalence and may slightly 
overestimate the prevalence in the population. 
Prevalence in non drug users in medium risk prisons 
• The prevalence of hepatitis B among those residing in medium risk prisons and who 
also reported never injecting drugs was 1.1% (4/372), 95% CI 0.29-2.7. 
• The prevalence of hepatitis C among those residing in medium risk prisons and who 
also reported never injecting drugs was 2.7% (10/372), 95% CI 0.17-2.3. 
The above two sets of assumptions were applied to the numbers in the low risk prisons to 
estimate the numbers of infected persons in these prisons. 
The estimated number of cases in low risk prisons based on the above assumptions were for: 
• Hepatitis B, between 2 and 9 cases 
• Hepatitis C, between 5 and 19 cases 
• HIV, between 0 and 9 cases 
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